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Abstract 
Potassium clavulanate is the sodium salt of clavulanic acid which is 
a β-lactam weak antibiotic. It is highly moisture sensitive; therefore it is 
generally supplied with the combination of diluents such as activated 
silicone dioxide and microcrystalline cellulose. 
Purpose 
The aim of this study is to enhance the stability of potassium 
clavulanate (P.C.) against moisture by microencapsulating the drug using 
spray drying technique.  
Methodology 
A ready mix of equal parts (1:1) of potassium clavulanate and 
silicone dioxide (PC/SiO2) was used as a core material. Acetone, absolute 
alcohol, isopropyl alcohol, chloroform, dichloromethane and diethyl ether 
were screened as solvents for coating. Potassium clavulanate was mixed 
with each solvent separately and tested visually to detect any color change. 
Four organic solvents were selected; acetone, chloroform, dichloromethane 
and diethyl ether since they gave the best results. Four different coating 
polymers were investegated; Eudragit E, glyceryl monostearate, ethyl 
cellulose and shellac. Eudragit was selected as the most apprpriate coating 
polymer in the ratio of 1:1 (Eudragit E: PC/SiO2) and acetone was used as a 
solvent in the microencapsulation using a laboratory scale spray dryer. The 
resultant microcapsules were subjected to different tests; visually for color 
change, particle size range determination, coating efficiency, yield and 
dissolution tests. The microcapsules in the powder form were also 
subjected to stability study for two months at 30°C and 65% R.H., 40°C 
and 75% R.H. and 45°C and 75% R.H. A stability study for the 
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reconstituted powder has been performed at ambient temperature for six 
days. 
Results 
A particle size range of less than 63µ has been achieved. It has been 
found that about 30% of the drug was completely coated. The dissolution 
of P.C. was 76% after 30 minutes while 87.4% was obtained from the 
Reference Brand product. USP30-NF25 states that not less than 80% 
should be dissolved in 30 minutes. 
It has been found that the coated P.C. was more stable than the 
uncoated drug in the first three days. However in the last three days the 
coated drug exhibited fast degradation. The coated drug was more stable at 
40ºC and 75% R.H. 
Conclusions 
It was concluded that P.C. and other moisture sensitive compounds 
can be protected from moisture by microencapsulation using spray drying 
technique. Type of solvents and coating material as well as the spray drying 
conditions play an important role in the final product and its specifications 
including the drug release and dissolution.  
Adjusting the spray dryer parameters such as liquid flow rate and 
compressed air pressure as well as selection of proper nebulizer may 
improve the final yield. 
Complete coating could be achieved by the addition of a suitable 
plasticizer to prevent the breakdown of the film coat. The coating material 
as well as the plasticizer should be carefully selected since they may affect 
the dissolution of potassium clavulanate. It was recommended that the 
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plasticizer should have enough water solubility in order to improve the 
dissolution without affecting the stability against moisture. 
v  
  اﻷﻃﺮوﺣﺔﺴﺘﺨﻠﺺﻣ
 
ﺗﻌﺘﺒﺮ ﻣﺎدة آﻼﻓﻮﻻﻧﺎت اﻟﺒﻮﺗﺎﺳﻴﻮم ﻣﻠﺢ ﻟﺤﺎﻣﺾ آﻼﻓﻮﻻﻧﻚ ،وﺗﻨﺪرج ﺿﻤﻦ ﻣﺠﻤﻮﻋﺔ اﻟﻤﻀﺎدات 
وهﺬﻩ اﻟﻤﺎدة ﺷﺪﻳﺪة اﻟﺘﺄﺛﺮ ﺑﺎﻟﺮﻃﻮﺑﺔ ﻟﺬا ﻳﺘﻢ إﻧﺘﺎﺟﻬﺎ و ﺗﻮزﻳﻌﻬﺎ .اﻟﺤﻴﻮﻳﺔ اﻟﺘﺎﺑﻌﺔ ﻟﻤﺮآﺒﺎت ﺑﻴﺘﺎﻻآﺘﺎم 
ﻟﺴﻴﻠﻜﻮن اﻟﻨﺸﻂ أو ﻣﺎدة ﻋﻠﻲ هﻴﺌﺔ ﺧﻠﻴﻂ ﻣﻦ ﻣﻮاد ﻣﺨﻔﻔﺔ ﺗﺤﻤﻴﻬﺎ ﻣﻦ اﻟﺮﻃﻮﺑﺔ ﻣﺜﻞ ﺛﺎﻧﻲ أآﺴﻴﺪ ا
  .اﻟﺴﻴﻠﻴﻠﻮز
 اﻟﻬﺪف
إن اﻟﻬﺪف ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ هﻮ زﻳﺎدة ﺛﺒﺎت ﻣﺎدة آﻼﻓﻮﻻﻧﺎت اﻟﺒﻮﺗﺎﺳﻴﻮم وذﻟﻚ ﺑﺎﻟﺘﻐﻠﻴﻒ اﻟﺪﻗﻴﻖ 
ﻟﻠﺠﺰﻳﺌﺎت أي إﺣﺎﻃﺔ اﻟﺠﺰﻳﺌﺎت اﻟﺪﻗﻴﻘﺔ ﻟﻠﻤﺮآﺐ ﺑﻤﺎدة ﻣﻘﺎوﻣﺔ ﻟﻠﺮﻃﻮﺑﺔ وﺗﺴﻤﻰ هﺬﻩ اﻟﺘﻘﻨﻴﺔ اﺣﺘﻮاء 
  .اﻟﺠﺰﻳﺌﺎت اﻟﺪﻗﻴﻘﺔ
 اﻟﻄﺮﻳﻘﺔ
ﺣﻴﺚ ﺗﻢ اﺳﺘﺨﺪام اﻟﻤﺎدة اﻟﻤﺘﻮﻓﺮة آﻨﻮاة ﻟﻠﺘﻐﻠﻴﻒ وهﻲ . ﺒﻌﺔ هﻲ ﻃﺮﻳﻘﺔ ﺗﺠﻔﻴﻒ اﻟﺮذاذاﻟﻄﺮﻳﻘﺔ اﻟﻤﺘإن  
  1:1ﻋﺒﺎرة ﻋﻦ ﺧﻠﻴﻂ ﻣﻦ آﻼﻓﻮﻻﻧﺎت اﻟﺒﻮﺗﺎﺳﻴﻮم ﻣﻊ ﺛﺎﻧﻲ أآﺴﻴﺪ اﻟﺴﻴﻠﻜﻮن ﺑﻨﺴﺒﺔ 
آﺤﻮل إﻳﺰوﺑﺮوﺑﺎﻳﻞ ، ، أﺳﻴﺘﻮن ،اﻟﻜﺤﻮل اﻟﻨﻘﻲ: ﺗﻢ ﻓﺤﺺ ﻋﺪد ﻣﻦ اﻟﻤﺬﻳﺒﺎت اﻟﻌﻀﻮﻳﺔ وهﻲ 
ﺣﻴﺚ ﺗﻢ ﻣﺰج آﻼﻓﻮﻻﻧﺎت اﻟﺒﻮﺗﺎﺳﻴﻮم ﻣﻊ آﻞ ﻣﺬﻳﺐ . إﻳﺜﻴﻞ إﻳﺜﺮ آﻠﻮروﻓﻮرم،داي آﻠﻮرو ﻣﻴﺜﺎن وداي
وﻣﻦ ﺛﻢ اﺧﺘﻴﺎر أرﺑﻌﺔ ﻣﺬﻳﺒﺎت ﻋﻀﻮﻳﺔ ﻻﺳﺘﺨﺪاﻣﻬﺎ . ﻋﻠﻰ ﺣﺪﻩ، ﺛﻢ ﻣﻼﺣﻈﺔ ﺗﻐﻴﺮ اﻟﻠﻮن ﻓﻲ آﻞ ﺧﻠﻴﻂ 
أرﺑﻌﺔ . وهﻲ أﺳﻴﺘﻮن ، آﻠﻮروﻓﻮرم،داي آﻠﻮرو ﻣﻴﺜﺎن وداي إﻳﺜﻞ إﻳﺜﺮ. ﻓﻲ ﺟﻬﺎز ﺗﺠﻔﻴﻒ اﻟﺮذاذ
 راﺟﻴﺖ إي ،ﺟﻠﻴﺴﺮﻳﻞ أﺣﺎدي اﻹﺳﺘﻴﺎرات ، إﻳﺜﻴﻞ ﺳﻴﻠﻴﻠﻮز ﻣﻐﻠﻔﺎت ﻋﻀﻮﻳﺔ ﺗﻢ ﻓﺤﺼﻬﺎ وهﻲ ﻳﻮد
ﻳﻮد راﺟﻴﺖ إي  )1:1وﺟﺪ أن أﻧﺴﺐ هﺬﻩ اﻟﻤﻮاد اﻟﻤﻐﻠﻔﺔ هﻲ ﻣﺎدة ﻳﻮد راﺟﻴﺖ إي وﺑﻨﺴﺒﺔ . وﺷﻴﻼك
آﻤﺎ وﺟﺪ أن اﻟﻤﺬﻳﺐ اﻟﻌﻀﻮي أﺳﻴﺘﻮن هﻮ أﻧﺴﺐ اﻟﻤﻮاد ﻻﺳﺘﺨﺪاﻣﻬﺎ ﻓﻲ ( ﺧﻠﻴﻂ آﻼﻓﻮﻻﻧﺎت ﺑﻮﺗﺎﺳﻴﻮم:
  .ﻲ ﺟﻬﺎز ﺗﺠﻔﻴﻒ اﻟﺮذاذإذاﺑﺔ ﻳﻮد راﺟﻴﺖ إي واﺳﺘﺨﺪاﻣﻬﺎ ﻓ
 اﻟﻔﺤﺺ ، ﻓﺤﺺ ﺣﺠﻢ اﻟﺠﺰﻳﺌﺎت اﻟﻨﺎﺗﺠﺔ أﺧﻀﻌﺖ اﻟﺠﺰﻳﺌﺎت اﻟﻤﺤﺘﻮاة ﻟﻌﺪد ﻣﻦ اﻟﻔﺤﻮﺻﺎت ﻣﺜﻞ
وﻓﺤﺺ .، ﻓﺤﺺ اﻟﻨﺎﺗﺞ اﻟﻨﻬﺎﺋﻲ (اﻻﺣﺘﻮاء)اﻟﺒﺼﺮي ﻟﻠﺘﺄآﺪ ﻣﻦ ﺗﻐﻴﺮ اﻟﻠﻮن ، ﻓﺤﺺ آﻔﺎءة اﻟﺘﻐﻠﻴﻒ 
  (.7002)اﻟﺬوﺑﺎن ﺣﺴﺐ دﺳﺘﻮر اﻷدوﻳﺔ اﻷﻣﺮﻳﻜﻲ 
 م ورﻃﻮﺑﺔ º03ة ﻟﺪراﺳﺔ اﻟﺜﺒﺎت ﻟﻤﺪة ﺷﻬﺮﻳﻦ ﻋﻨﺪ درﺟﺔ ﺣﺮارة آﻤﺎ ﺗﻢ إﺧﻀﺎع اﻟﺠﺰﻳﺌﺎت اﻟﻤﺤﺘﻮا
 م ورﻃﻮﺑﺔ º54وﻋﻨﺪ درﺟﺔ ﺣﺮارة %. 57 م ورﻃﻮﺑﺔ ﻧﺴﺒﻴﺔ º04وﻋﻨﺪ درﺟﺔ ﺣﺮارة %. 56ﻧﺴﺒﻴﺔ 
iv  
آﻤﺎ ﺗﻢ إﺧﻀﺎع اﻟﺠﺰﻳﺌﺎت اﻟﻤﺤﺘﻮاة ﺑﻌﺪ ﺧﻠﻄﻬﺎ ﺑﺎﻟﻤﺎء وﺣﻔﻈﻬﺎ ﻓﻲ درﺟﺔ ﺣﺮارة اﻟﻐﺮﻓﺔ %. 57ﻧﺴﺒﻴﺔ 
  .ﻟﻤﺪة ﺳﺘﺔ أﻳﺎم
 اﻟﻨﺘﺎﺋﺞ
ﻓﻘﻂ ﻣﻦ ﻣﺎدة  % 03آﻤﺎ وﺟﺪ ان .  ﻣﻴﻜﺮون36ﺣﺠﻢ اﻟﺠﺰﻳﺌﺎت اﻟﻨﺎﺗﺠﺔ اﻗﻞ ﻣﻦ وﺟﺪ أن ﻣﺪى 
آﻤﺎ وﺟﺪ أن ﻣﻌﺪل ذوﺑﺎن اﻟﻤﺎدة اﻟﻤﺤﺘﻮاة هﻮ . آﻼﻓﻮﻻﻧﺎت اﻟﺒﻮﺗﺎﺳﻴﻮم ﺗﻢ اﺣﺘﻮاء ﺟﺰﻳﺌﺎﺗﻬﺎ ﺑﺎﻟﻜﺎﻣﻞ 
( 7002)ﻟﻠﺼﻨﻒ اﻟﺘﺠﺎري اﻟﻤﺮﺟﻌﻲ ﻋﻠﻤﺎ أن دﺳﺘﻮر اﻷدوﻳﺔ اﻷﻣﺮﻳﻜﻲ % 4.78ﻣﻘﺎرﻧﺔ ب% 67
  . ددﻗﻴﻘﺔ03ﺧﻼل % 08ﺔ اﻟﻤﺎدة اﻟﺬاﺋﺒﺔ ﻋﻦ ﻳﻨﺺ ﻋﻠﻰ أﻻ ﺗﻘﻞ ﻧﺴﺒ
أﺗﻀﺢ ﻣﻦ دراﺳﺔ اﻟﺜﺒﺎت أن ﺛﺒﺎت اﻟﻤﺎدة اﻟﻤﺤﺘﻮاة آﺎن أﻓﻀﻞ ﻣﻦ اﻟﻤﺎدة اﻟﻐﻴﺮ ﻣﻌﺎﻟﺠﺔ ﻋﻨﺪ درﺟﺔ 
  .رﻃﻮﺑﺔ ﻧﺴﺒﻴﻪ% 57 م وº04ﺣﺮارة 
 اﻻﺳﺘﻨﺘﺎج
ﻳﺴﺘﻨﺘﺞ ﻣﻤﺎ ﺳﺒﻖ أن ﻣﺎدة آﻼﻓﻮﻻﻧﺎت اﻟﺒﻮﺗﺎﺳﻴﻮم وﺑﻌﺾ اﻟﻤﺮآﺒﺎت اﻟﺤﺴﺎﺳﺔ ﻟﻠﺮﻃﻮﺑﺔ ﻳﻤﻜﻦ زﻳﺎدة 
ﻬﺎ وﻣﻘﺎوﻣﺘﻬﺎ ﻟﻠﺮﻃﻮﺑﺔ ﻋﻦ ﻃﺮﻳﻖ اﻻﺣﺘﻮاء اﻟﺠﺰﻳﺌﻲ اﻟﺪﻗﻴﻖ ﻟﻬﺬﻩ اﻟﻤﻮاد ﺑﺎﺳﺘﺨﺪام ﺗﻘﻨﻴﺔ ﺗﺠﻔﻴﻒ ﺛﺒﺎﺗ
  .اﻟﺮذاذ 
إن ﻧﻮﻋﻴﺔ اﻟﻤﺎدة اﻟﻤﺬﻳﺒﺔ وﻧﻮﻋﻴﺔ اﻟﻤﺎدة اﻟﻤﻐﻠﻔﺔ ﺑﺎﻹﺿﺎﻓﺔ إﻟﻲ اﻟﻈﺮوف اﻟﺘﻲ ﺗﻢ ﺗﺸﻐﻴﻞ ﺟﻬﺎز اﻟﺘﺠﻔﻴﻒ 
  .ﻋﻠﻴﻬﺎ هﻲ ﻋﻮاﻣﻞ ﻣﻬﻤﺔ ﺟﺪا ﻓﻲ ﺗﺤﺪﻳﺪ ﻣﻮاﺻﻔﺎت اﻟﻨﺎﺗﺞ ﺧﺎﺻﺔ اﻟﺬوﺑﺎن
 ﻣﻮاﺻﻔﺎت ﺟﻬﺎز ﺗﺠﻔﻴﻒ اﻟﺮذاذ ﻣﺜﻞ ﻣﻌﺪل ﺿﺦ اﻟﺴﺎﺋﻞ، ﻗﻮة ﺿﻐﻂ اﻟﻬﻮاء اﻟﻤﻀﻐﻮط إن ﺿﺒﻂ
  .وﺗﺤﺪﻳﺪ ﻧﻮﻋﻴﺔ اﻟﺒﺎﻋﺚ ﻟﻠﺮذاذ ﻳﻤﻜﻦ أن ﻳﺤﺴﻦ ﻣﻦ زﻳﺎدة اﻟﻨﺎﺗﺞ اﻟﻨﻬﺎﺋﻲ
وﻟﻠﺤﺼﻮل ﻋﻠﻲ ﺗﻐﻠﻴﻒ أو اﺣﺘﻮاء آﺎﻣﻞ ﻟﻠﺠﺰﻳﺌﺎت ﻳﻤﻜﻦ إﺿﺎﻓﺔ ﻣﺎدة ﻣﻦ اﻟﻤﻮاد اﻟﻤﻠﺪﻧﻪ واﻟﺘﻲ ﺗﺴﺎﻋﺪ 
ﻟﺬا ﻳﺠﺐ اﺧﺘﻴﺎر اﻟﻤﺎدة اﻟﻤﻐﻠﻔﺔ وآﺬا اﻟﻤﺎدة . ﻟﺘﺨﻔﻴﻒ أوأﺛﻨﺎء اﻟﺤﻔﻆ ﻋﻠﻲ ﻣﻨﻊ ﺗﻜﺴﺮ اﻟﻤﺎدة اﻟﻤﻐﻠﻔﺔ ﺑﻌﺪ ا
اﻟﻤﻠﺪﻧﻪ ﺑﻌﻨﺎﻳﺔ ﻓﺎﺋﻘﺔ وذﻟﻚ ﻟﻠﻤﺤﺎﻓﻈﺔ ﻋﻠﻲ ﺧﺎﺻﻴﺔ ذوﺑﺎﻧﻲ ﻣﺎدة آﻼﻓﻮﻻﻧﺎت اﻟﺒﻮﺗﺎﺳﻴﻮم وﻋﻠﻴﻪ ﻋﻨﺪ 
اﺧﺘﻴﺎر اﻟﻤﺎدة اﻟﻤﻠﺪﻧﺔ ﻳﺠﺐ أن ﺗﻜﻮن ﻟﻬﺎ ﻗﺪرة ﻣﺤﺪودة ﻋﻠﻰ اﻟﺬوﺑﺎﻧﻴﺔ ﻓﻲ اﻟﻤﺎء وذﻟﻚ ﻟﺘﺤﺴﻴﻦ ذوﺑﺎن 
  .ﻧﻔﺲ اﻟﻮﻗﺖ اﻟﻤﺤﺎﻓﻈﺔ ﻋﻠﻰ ﺛﺒﺎﺗﻪ ﺿﺪ اﻟﺮﻃﻮﺑﺔاﻟﺪواء وﻓﻰ 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1. Introduction 
 
Chemotherapy is the term originally used to describe the use of 
drugs that are 'selectively toxic' to invading micro-organisms while having 
minimal effects on the host. The term also embraces the use of drugs that 
target tumours. 
Chemotherapeutic agents then, are chemicals that are intended to be 
toxic for the pathogenic organism and/or cancer cells but innocuous to the 
host (Rang and Dale, 2007). 
 
1.1.1 Antibacterial Agents  
Antibacterial agents are chemical substances that kill or inhibit the 
growth of bacteria. 
The antibacterial agents can be classified into specific classes as well 
as divided into five major groups according to their primary mechanism of 
action or cellular biochemical pathway that is inhibited. The antibiotics and 
systemic antibacterial agents are grouped into the following categories: 
inhibition of bacterial cell wall synthesis (penicillins, cephalosporins, 
carbabenems and vancomycin), damage to cytoplasmic membrane 
(polymexins), modification of synthesis or metabolism of nucleic acids 
(quinolones, rifampicin and nitrfurantoin), inhibition of protein synthesis 
(aminoglycosides, tetracyclines, chloramphenicol, erythromycin and 
clindamycin) and folate-inhibitors or modification of energy metabolism 
(sulfonamides and trimethoprim) (Steven Gelone, 2000). 
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1.1.1.1 Antibiotics 
In the strictest sense, antibiotics are antibacterial substances 
produced by various species of microorganisms (bacteria, fungi, and 
actinomycetes) that suppress the growth of other microorganisms. Common 
usage often extends the term antibiotics to include synthetic antimicrobial 
agents, such as sulfonamides and quinolones. Antibiotics differ markedly in 
physical, chemical, and pharmacological properties, in antimicrobial spectra, 
and in mechanisms of action. Knowledge of molecular mechanisms of 
bacterial replication has greatly facilitated rational development of 
compounds that can interfere with their replication (Goodman and Gilman, 
2006). 
 
1.1.1.2 β -lactam antibiotics 
The β -lactam antibiotics are useful and frequently prescribed 
antimicrobial agents that share a common structure and mechanism of 
action; inhibition of synthesis of the bacterial peptidoglycan cell wall. This 
class includes penicillins G and V, which are highly active against 
susceptible gram-positive cocci; penicillinase-resistant penicillins such as 
nafcillin, which are active against penicillinase-producing Staphylococcus 
aureus; ampicillin and other agents with an improved gram-negative 
spectrum, especially when combined with a β -lactamase inhibitor; and 
extended-spectrum penicillins with activity against Pseudomonas 
aeruginosa, such as piperacillin.  
The β -lactams also include the cephalosporin antibiotics, which are 
classified by generation: First-generation agents have excellent gram-
positive and modest gram-negative activity; second-generation agents have 
somewhat better activity against gram-negative organisms and include some 
agents with antianaerobe activity; third-generation agents have activity 
against gram-positive organisms and much more activity against the 
Enterobacteriaceae, with a subset activity against P. aeruginosa; and 
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fourth-generation agents encompass the antimicrobial spectrum of all the 
third-generation agents and have increased stability to hydrolysis by 
inducible chromosomal β -lactamases. 
β -Lactamase inhibitors such as clavulanate are used to extend the 
spectrum of penicillins against β -lactamase-producing organisms. 
Carbapenems, including imipenem and meropenem, have the broadest 
antimicrobial spectrum of any antibiotic, whereas the monobactam 
aztreonam has a gram-negative spectrum resembling that of the 
aminoglycosides.  
Bacterial resistance against the β -lactam antibiotics continues to 
increase at a dramatic rate. Mechanisms of resistance include not only 
production of β -lactamases that destroy the antibiotics but also alterations in 
or acquisition of novel penicillin-binding proteins and decreased entry 
and/or active efflux of the antibiotic (Goodman and Gilman, 2006). 
 
1.1.1.2.1. Mechanism of Action 
Penicillins, like all β-lactam antibiotics, inhibit bacterial growth by 
interfering with a specific step in bacterial cell wall synthesis. The cell wall 
is a rigid outer layer that is not found in animal cells. It completely 
surrounds the cytoplasmic membrane (Figure 1.1.), maintaining the shape of 
the cell and preventing cell lysis from high osmotic pressure. The cell wall 
is composed of a complex crosslinked polymer, peptidoglycan (murein, 
mucopeptide), consisting of polysaccharides and polypeptides. The 
polysaccharide contains alternating amino sugars, N-acetylglucosamine and 
N-acetylmuramic acid  
A five-amino-acid peptide is linked to the N-acetylmuramic acid 
sugar. This peptide terminates in D-alanyl-D-alanine. Penicillin-binding 
proteins (PBPs) catalyze the transpeptidase reaction that removes the 
terminal alanine to form a crosslink with a nearby peptide, which gives cell 
wall its structural rigidity. β -Lactam antibiotics are structural analogs of the 
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natural D-Ala-D-Ala substrate and they are covalently bound by PBPs at the 
active site. After a β –lactam antibiotic has attached to the PBP, the 
transpeptidation reaction is inhibited, peptidoglycan synthesis is blocked, 
and the cell dies. The exact mechanism responsible for cell death is not 
completely understood, but autolysins, bacterial enzymes that remodel and 
break down cell wall, are involved. Penicillins and cephalosporins are 
bactericidal only if cells are actively growing and synthesizing cell wall 
(Katzung, 2005). 
 
 
Figure (1.1) a simplified diagram of the cell envelope of a gram-negative bacterium. 
The outer membrane, a lipid bilayer, is present in gram-negative but not gram-positive 
organisms. It is penetrated by porins, proteins that form channels providing hydrophilic 
access to the cytoplasmic membrane. The peptidoglycan layer is unique to bacteria and is 
much thicker in gram-positive organisms than in gram-negative ones. Together, the outer 
membrane and the peptidoglycan layer constitute the cell wall. Penicillin-binding 
proteins (PBPs) are membrane proteins that cross-link 
peptidoglycan. -lactamases, if present, reside in the periplasmic space or on the outer 
surface of the cytoplasmic membrane, where they may destroy -lactam antibiotics that 
penetrate the outer membrane (Source: Katzung, 2005). 
 
 
1.1.1.2.2 β -lactam preparations 
 
Some β -lactam preparations and dosage form are summarized in 
Table (1.1) 
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Table (1.1) selected β-lactam preparations and their dosage form (Kutzung, 2005). 
product Rout of administration Dosage form and strength 
Amoxicillin Oral 
tablets 500, 875 mg; 
capsules; 250, 500 mg 
Powder to reconstitute for 50, 125, 200, 
250, 400 mg/mL solution.  
Amoxicillin/potassium 
clavulanate 
(Clavulanate content varies with 
the formulation) 
Oral 
tablets 250, 500, 875 mg; 
chewable tablets 125, 200, 250, 400 mg; 
extended release tablet 1000 mg 
powder to reconstitute for 125, 200, 250 
mg/5 mL suspension 
Ampicillin 
Oral 
 
parenteral 
capsules 250, 500 mg; 
powder to reconstitute for 125, 250 
mg/5ml suspensions: powder to 
reconstitute for injection (125, 250, 500 
mg, 1, 2 g per vial) 
Penicillin G  
Oral 
 
 
 
Parenteral 
Tablets: l: 0.2, 0.25, 0.4, 0.5, 0.8 million 
unit; powder to reconstitute 400,000 
units/5 mL suspension 
powder to reconstitute for injection (1, 2, 
3, 5, 10, 20 million units) 
Penicillin G procaine 
 Parenteral 0.6, 1.2 million units/mL for IM injection  
Penicillin V  
 Oral 
Tablets: 250, 500 mg; 
powder to reconstitute for 125, 250 mg/5 
mL solution 
Penicillin G benzathine  Parenteral 0.6, 1.2, 2.4 million units per dose 
Ticarcillin/clavulanate 
potassium Parenteral 
powder to reconstitute for injection (1, 3, 
6 g per vial) Clavulanate content 0.1 g 
Cefadroxil Oral 
Capsules: 500 mg; 
Tablets: 1 g; 
Powder for suspension 125, 250, 500 
mg/5 mL 
Cefazolin  
 Parenteral 
powder to reconstitute for injection (0.25, 
0.5, 1 g per vial or IV piggyback unit 
Cephalexin 
 Oral 
250, 500 mg capsules and tablets; 1 g 
tablets; 125, 250 mg/5 mL suspension 
Cephradine 
 
Oral 
 
Parenteral 
Capsule:250, 500 mg 
Powder for suspension 125, 250 mg/5 mL 
powder to reconstitute for injection: (0.25, 
0.5, 1, 2 g per vial) 
Cefuroxime 
 
Oral 
 
Parenteral 
Tablets: 125, 250, 500 mg; 
powder for suspension: 125, 250 mg/5 mL 
powder to reconstitute for injection (0.75, 
1.5 g per vial or infusion pack 
Cefaclor 
 Oral 
Capsules:250, 500 mg; 
extended-release tablets: 375, 500 mg; 
powder to reconstitute for 125, 250, 375 
mg/5 mL suspension 
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1.1.1.2.3 Mechanisms of Bacterial Resistance to Penicillins and 
Cephalosporins  
Although all bacteria with cell walls contain PBPs, β -lactam 
antibiotics cannot kill or even inhibit all bacteria because by various 
mechanisms bacteria can be resistant to these agents. The microorganism 
may be intrinsically resistant because of structural differences in the PBPs 
that are the targets of these drugs. Furthermore, a sensitive strain may 
acquire resistance of this type by the development of high-molecular-weight 
PBPs that have decreased affinity for the antibiotic. Because the β -lactam 
antibiotics inhibit many different PBPs in a single bacterium, the affinity for 
β -lactam antibiotics of several PBPs must decrease for the organism to be 
resistant. Altered PBPs with decreased affinity for β -lactam antibiotics are 
acquired by homologous recombination between PBP genes of different 
bacterial species. Four of the five high-molecular-weight PBPs of the most 
highly penicillin-resistant Streptococcus pneumoniae isolates have 
decreased affinity for β -lactam antibiotics as a result of interspecies 
homologous recombination events. In contrast; isolates with high-level 
resistance to third-generation cephalosporins contain alterations of only two 
of the five high-molecular-weight PBPs because the other PBPs have 
inherently low affinity for the third-generation cephalosporins. Penicillin 
resistance in Streptococcus sanguis and other viridans streptococci 
apparently emerged as a result of replacement of its PBPs with resistant 
PBPs from S. pneumoniae. Methicillin-resistant S. aureus are resistant via 
acquisition of an additional high-molecular-weight PBP (via a transposon 
from an unknown organism) with a very low affinity for all β -lactam 
antibiotics. The gene (MecA) encoding this new PBP also is present in and 
responsible for methicillin resistance in the coagulase-negative 
staphylococci (Goodman and Gilman, 2006). 
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1.1.1.2.4 Clavulanic acid (potassium salt) 
 
 
Structural formula of potassium clavulanate 
Clavulanic acid has a beta-lactam structure resembling that of the 
penicillin nucleus, except that the fused thiazolidine ring of the penicillins is 
replaced by an oxazolidine ring. In general, clavulanic acid has only weak 
antibacterial activity. It is a potent progressive inhibitor of plasmid-mediated 
and some chromosomal beta-lactamases produced by Gram-negative 
bacteria including Haemophilus ducreyi, H. influenzae, Neisseria 
gonorrhoeae, Moraxella catarrhalis (Branhamella catarrhalis), Bacteroides 
fragilis, and some Enterobacteriaceae. It is also an inhibitor of the β -
lactamases produced by Staphylococcus aureus. Clavulanic acid can 
permeate bacterial cell walls and can therefore inactivate both extracellular 
enzymes and those that are bound to the cell. Its mode of action depends on 
the particular enzyme inhibited, but it generally acts as a competitive, and 
often irreversible, inhibitor. Clavulanic acid consequently enhances the 
activity of penicillin and cephalosporin antibacterials against many resistant 
strains of bacteria. However, it is generally less effective against 
chromosomally mediated type 1 β -lactamases; therefore, many Citrobacter, 
Enterobacter, Morganella, and Serratia spp., and Pseudomonas aeruginosa 
remain resistant. Some plasmid-mediated extended-spectrum beta-
lactamases in Klebsiella pneumoniae, some other Enterobacteriaceae, and 
Pseudomonas. aeruginosa are also not inhibited by beta-lactamase inhibitors 
(Martindale, 2005). 
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Clavulanic acid is given as potassium clavulanate by mouth and 
injection in combination with amoxicillin (Co-amoxiclav) and by injection 
in combination with ticarcillin (Martindale, 2005). 
Use of clavulanate with penicillins has been associated with the 
development of cholestatic jaundice and hepatitis and therefore the use of 
co-amoxiclav has declined. Because of the risk of cholestatic jaundice Co-
amoxiclav is not a treatment of choice for common bacterial infections. The 
UK Committee on Safety of Medicines recommends that it should be 
reserved for bacterial infections likely to be caused by amoxicillin-resistant 
beta-lactamase-producing strains and that treatment should not usually 
exceed 14 days. It may be considered for the following main indications:  
- Sinusitis, otitis media, recurrent tonsillitis and acute exacerbations of 
chronic bronchitis  
- Bronchopneumonia and urinary-tract infections, especially when 
recurrent or complicated, but not prostatitis  
- Septic abortion, pelvic or puerperal sepsis, and intra-abdominal sepsis  
- Cellulitis, animal bites, and severe dental abscess with spreading 
cellulitis. (Martindale, 2005) 
The Molecular Formulae of Clavulanate potassium (C.P.) is C8H9NO5. 
It has a molecular weight of 237.5gm. Its Chemical name is Potassium (2R, 
3Z, 5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo [3.2.0] heptane-
2-carboxylate. It is a white or almost white, crystalline hygroscopic powder. 
It is freely soluble in water, slightly soluble in alcohol, very slightly soluble 
in acetone (British Pharmacopoeia, 2008). 
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1.1.1.2.5 Diluted Potassium Clavulanate: 
It is a dry mixture of potassium clavulanate and cellulose, 
microcrystalline or silica, colloidal anhydrous or colloidal hydrated silica. It 
is white or almost white powder, hygroscopic (British Pharmacopoeia, 
2008). 
It is moisture-sensitive freely soluble in water, but stability in 
aqueous solution is not good, optimum stability is at a pH 6.0 to 6.3. It is 
soluble in methanol, with decomposition (USP30-NF25, 2007). 
 
 
1.1.2 Microencapsulation: 
Microencapsulation, as a process, is a means of applying relatively 
thin coatings to small particles of solids or droplets of liquids and 
dispersions. Microencapsulation provides the means of converting liquids to 
solids, of altering colloidal and surface properties, of providing 
environmental protection, and of controlling the release characteristics or 
availability of coated materials. Several of these properties can be attained 
by macropackaging techniques; however the uniqueness of 
microencapsulation is the small size of the coated particles and their 
subsequent use and adaptations to a wide variety of dosage forms and 
product applications. Because of the small size of the particles, drug 
moieties can be widely distributed throughout the gastrointestinal tract, thus 
potentially improving drug absorption. 
The application of microencapsulation might well include sustained-
release or prolonged-action medications, taste-masked chewable tablets, 
powders and suspensions, single-layer tablets containing chemically 
incompatible ingredients, and new formulation concepts for creams, 
ointments, aerosols, dressing, plasters, suppositories, and injectables. This 
technology does not exclude problem areas; for instance, no single 
microencapsulation process is adaptable to all core material candidates or 
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product applications. Difficulties, such as incomplete or discontinuous 
coating, inadequate stability or shelf life of sensitive pharmaceutical, 
nonreproducible and unstable release characteristics of coated products and 
economic limitations often are encountered in the attempt to apply a 
particular microencapsulation method to a specific task (Lachman, 1986). 
Microcapsules are small particles that contain an active agent or core 
material surrounded by a coating or shell (Benita, 2006). 
There is no universally accepted size range that particles must have 
in order to be classified as microcapsules. However many workers classify 
capsules smaller than 1µ as nanocapsules and capsules larger than 1000µ as 
macrocapsules. Microcapsules lay between 1µ and 1000µ. Commercially 
microcapsules typically have diameter between 3µ and 800µ and contain 10-
90 weight percent core. A wide range of core materials has been 
encapsulated, including adhesives, agrochemicals, live cells, active 
enzymes, fragrances, pharmaceutical, and inks. Most capsule shell materials 
are organic polymers, but fats and waxes are also used (Benita, 2006). 
 
1.1.2.1 Core material: 
The core material, defined as the specific material to be coated, can 
be liquid or solid in nature. The composition of the core material can be 
varied, as the liquid can include dispersed and/or dissolved material. The 
solid core can be a mixture of active constituents, stabilizers, diluents, 
excipients, and release-rate retardants or accelerators. The ability to vary the 
core material composition provides definite flexibility and utilization of this 
characteristic often allows effectual design and development of the desired 
microcapsule properties (Lachman, 1986). 
 
1.1.2.2 Coating materials 
The selection of appropriate coating material dictates, to a major 
degree, the resultant physical and chemical properties of the microcapsules, 
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and consequently, this selection must be given due consideration. The 
coating material should be capable of forming a film that is cohesive with 
the core material; be chemically compatible and non-reactive with the core 
material; and provides the desired coating properties, such as strength, 
flexibility, impermeability, optical properties and stability (Lashman, 1986). 
 
 
A partial listing of typical coating materials commonly used in the 
various microencapsulation methods is suggested in table (1.2) 
 
 
Table (1.2): Representative coating materials and applicable microencapsulation process 
processes 
Coating material Spray 
drying 
Solvent 
evaporation 
Phase 
separation-
coacervation 
Fluidized Bed 
Coating 
Gelatin √ √ √ √ 
Gum Arabic √ √ √ √ 
Povidone √ √ √ √ 
Carboxymethylcellulose √  √ √ 
Polyvinyl alcohol √ √ √ √ 
Ethyl cellulose √ √ √ √ 
Polymethacrylates √ √ √ √ 
Silicones √    
Paraffin √  √ √ 
Beeswax √   √ 
Stearic acid √    
Glyceryl stearates √   √ 
Shellac √  √ √ 
Source: Lachman, 1986 
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1.1.2.3 Microencapsulation techniques  
There are different types of techniques applied for 
microencapsulation: 
 
1.1.2.3.1 Spray drying and spray congealing: 
These two methods have been used for many years as 
microencapsulation techniques. Spray drying and Spray congealing 
processes are similar in that both involve dispersing the core material in a 
liquefied coating substance and spraying or introducing the core-coating 
mixture into same environmental conditions, whereby relatively rapid 
solidification (and formation) of the coating is effected. The principal 
difference between the two methods is the means by which coating 
solidification is accomplished. Coating solidification in the case of spray 
drying is effected by rapid evaporation of a solvent in which the coating 
material is dissolved. Coating solidification in spray congealing method, 
however, is accomplished by thermally congealing a molten coating 
material or by solidification of the dissolved coating by introducing the 
coating core mixture into a nonsolvent. Removal of the nonsolvent or 
solvent from the coated product is then accomplished by sorption, 
extraction, or evaporation techniques. 
In practice microencapsulation by spray drying is conducted by 
dispersing a core material in a coating solution, in which the coating 
substance is dissolved and in which the core material is insoluble, and then 
by atomizing the mixture into an air stream. The air, usually heated, supplies 
the latent heat of vaporization required to remove the solvent from the 
coating material, thus forming the microencapsulated product.  
Microencapsulation by spray congealing can be accomplished with 
spray drying equipment when the protective coating is applied as a melt. 
Coating solidification (and microencapsulation) is accomplished by spraying 
the hot mixture into a cool air stream (Lachman, 1986). 
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1.1.2.3.2 Emulsification–Solvent Removal Processes 
Initially, polymers are dissolved in a volatile organic solvent with low 
water miscibility, such as dichloromethane (DCM) or chloroform. The drugs 
are then dissolved or dispersed in the polymer solution. This mixture is then 
emulsified in a large volume of an aqueous phase containing tensioactive 
molecules such as polyvinyl alcohol (PVA), resulting in organic solvent 
droplets dispersed in a water phase—oil-in-water (O/W) emulsion. The 
emulsion is next subjected to solvent removal by either evaporation or an 
extraction process in order to generate microspheres. These particles are 
washed, collected by filtration, sieving, or centrifugation, and finally dried 
or lyophilized to provide free-flowing injectable microspheres. 
The two processes of solvent removal influence microsphere size and 
morphology. When the solvent is evaporated, the emulsion is maintained at 
reduced or atmospheric pressure under low agitation. If the drug molecules 
are volatile and/or have a great affinity for the organic phase, they can be 
removed at the same time. 
During the extraction process, the emulsion is transferred into a large 
volume of water (with or without surfactant) or another quench medium, 
where the solvent diffuses out. The quenching medium must not make the 
polymer soluble and must have a great affinity for the aqueous phase. It 
should be noted that the solvent evaporation process is similar to the 
extraction method, in that the solvent must first diffuse out into the external 
aqueous dispersion medium before it can be removed from the system by 
evaporation. The rate of solvent removal influences the characteristics of the 
microspheres. Rapid solvent removal leads to the formation of porous 
structures on the microsphere surface and to a hardening of the polymers in 
the amorphous state. Solvent removal by the extraction method is faster 
(generally less than 30 min) than by the evaporation process and hence, the 
microspheres generated by the former method are more porous and more 
amorphous. 
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1.1.2.3.3 Organic Phase Separation (Coacervation)  
The phase separation process has allowed the production of the first 
microspheres encapsulating a peptide (nafarelin acetate) for a parenteral 
application at an industrial scale. 
This process consists in decreasing the solubility of the 
encapsulating polymers (PLGA, PLGA-PEG, and PLA) solubilized in an 
organic solvent (DCM, ethyl acetate, chloroform, toluene) by varying the 
temperature, or by adding a third component that interacts with the organic 
solvent but not with the polymer [coacervating agent]. Classes of 
coacervating agents can be distinguished into: (i) nonsolvents of the 
polymer, that induce coacervation by extracting the polymer solvent, and (ii) 
polymers that are incompatible (nonmiscible) with the wall polymers. 
The drug that is dispersed or sometimes dissolved in the polymer 
solution is coated or entrapped by the droplet of coacervate. Then, the 
coacervate droplets are solidified by using a hardening agent such as 
heptane to produce microparticles (microcapsules or microspheres), which 
are collected by washing, sieving, filtration, or centrifugation, and are 
finally dried. The hardening agent should be relatively volatile and should 
easily remove the viscous coacervating agent on washing. 
This process is suitable to encapsulate both hydrophilic and 
hydrophobic drugs. Hydrophilic drugs such as peptides and proteins can be 
dissolved in water. 
The coacervating agent affects both phase separation and the 
solidification stages of the coacervation process. The coacervating agent 
should dissolve neither the polymer nor the drug and should be soluble in 
the solvent. It is added to the stirred polymer–drug–solvent system and 
gradually induces coacervation. The size of the resulting coacervate droplets 
is controlled by the stirring rate and by the rate of addition of the 
coacervating agent. The process conditions, like viscosity of the 
coacervating agent and type of polymer coating or polymer concentration, 
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that allow the obtaining of the ‘‘stability window’’ can be varied to obtain 
microparticles. For low coacervating agent volumes coacervation is not 
effective and stable coacervate droplets cannot be obtained. For high 
coacervating agent volumes, extensive aggregation and precipitation of 
coacervate droplets occur. 
Typical coacervating agents used with poly(α-hydroxyacid) are low 
(Mw) silicone oil (poly (dimethylsiloxane)), triglycerides, mineral oil, low 
(Mw) liquid polybutadiene, hexane and low (Mw) liquid methacrylic 
polymers. Hardening agents include aliphatic hydrocarbons such as hexane, 
heptane, octamethylcyclotetrasiloxane (OMCTS), and petroleum ether. 
Temperature parameters, polymer concentrations, and (Mw) must be 
carefully adjusted to obtain physically stabilized droplets made of poly(α -
hydroxy acid)s-rich phase surrounded by the poly(a-hydroxyacid)-poor 
phase. Thus, interfacial properties and viscosity will play key roles. 
Moreover, the entrapment of dissolved/ dispersed drugs in the coacervate 
phase must be carried out with conditions that do not affect the activity of 
the compound. 
In a sophisticated process, poly(lactide) (PLA) solution was injected 
into mineral oil, whereby particles of any desirable size were produced by 
varying the diameter of the injection equipment. Other modifications of the 
classical coacervation procedure were made for encapsulation of nafarelin 
acetate. These studies combined a phase-separation followed by a solvent-
evaporation step to obtain freely flowing powders. 
In the coacervation process, phase equilibrium is never reached. 
Therefore, the formulation and process variables significantly affect the 
kinetics of the entire process and ultimately the characteristics of the 
microspheres. Moreover, the coacervate droplets are extremely sticky and 
adhere to each other before completion of the phase separation operation or 
before hardening. Consequently, this technique tends to produce 
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agglomerated particles. However, adjusting the stirring rate, temperature, or 
the addition of a stabilizer is known to rectify this problem. 
Compared to the solvent evaporation–extraction method, the choice 
of solvents is less stringent because the solvent does not need to be 
immiscible with water and its boiling point can be higher than that of water. 
However, the method also requires large quantities of organic components 
(initial solvent and hardening agent), which are often difficult to remove 
from the final microspheres. 
In an attempt to minimize the amount of residual solvents, a low 
ratio of solvent/ coacervating agent [Polydimethylsiloxane (PDMS)] was 
claimed to be a key parameter in controlling the amount of the residual 
hardening agent heptane in histreline-loaded PLGA microspheres. The 
suitability of volatile siloxanes such as OMCTS or hexadimethylsiloxane, as 
hardening agents was shown in the encapsulation of the peptide drug 
triptorelin. The residual amount of siloxane in the final product was 2% to 5 
% (Benita, 2006). 
 
1.1.2.3.4 Fluidized Bed Coating  
Conventional coating processes in fluidized beds are carried out by 
atomizing droplets of coating material solution through a nozzle into a hot 
gas fluidized particle bed. After the atomized droplets of coating material 
came into contact with the core particles, the solvent has to evaporate 
quickly; hence an excess of droplets in the bed would induce agglomeration. 
Therefore, suitable droplet atomizing and drying conditions are essential to 
avoid the unplanned agglomeration of solid particles. However, 
uncontrollable agglomeration often takes place especially for fine particles 
(particle diameter <70 µm) because of their strong cohesive force. 
Therefore, it is difficult to coat fine particles by using conventional 
fluidized-bed coating processes. (Microencapsulation Benita, 2006) 
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1.1.2.3.5 Other techniques: 
a- Centrifugal extrusion 
b- Rational suspension separation 
c- Interfacial polymerization 
d- In situ polymerization  
(Benita, 2006). 
 
 
1.1.2.4 Spray Drying Microencapsulation 
Spray drying is traditionally used in the chemical, pharmaceutical, 
biochemical, and food industries for the drying of substances. For example, 
it is commonly used to process milk, ceramics, and various chemicals into a 
dry powder form. Therefore, information from food processing and 
chemical engineering is particularly relevant to pharmaceutical problems. 
The spray drying technique can be used to encapsulate sensitive substances 
such as fragrances, essential oils, or vitamins. The internal structure of the 
microparticles depends on the solubility of the drug in the polymer leading 
to monolithic microspheres with dispersed or dissolved drug substance. True 
microcapsules can be obtained by spraying a suspension of a drug in an 
organic solution of the polymer. By contrast, microspheres of solid solution 
or solid dispersion morphology are obtained by selection of appropriate 
process conditions and solvents. 
The principle of spray drying by nebulization is based on the 
atomization of a solution, containing drugs and carrier molecules, by using 
compressed air or compressed nitrogen through a desiccating chamber, and 
using a current of warm air for the drying process. This is performed in three 
steps: (i) formation of the aerosol, (ii) contact of the aerosol with the warm 
air and drying of the aerosol, and (iii) separation of the dried product and the 
air charged with the solvent. This process has been applied to the creation of 
microparticles by spraying complex liquid mixtures containing an active 
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principle that is dissolved/dispersed in an organic or aqueous polymer 
solution. The production of microspheres or microcapsules by spray drying 
depends on whether the initial formulation was in the form of a solution, 
suspension, or emulsion. It has been used successfully with several 
biodegradable polymers such as PLA, PLGA, poly(e-caprolactone) (PCL), 
commercial Eudragit (Degussa AG, Weiterstadt, Germany), gelatin, and 
polysaccharides or related biopolymers. 
Spray drying usually leads to a broad distribution of particle size, 
with a Gaussian shape, centered on 10 mm. Flow rate, nozzle geometry, and 
solution viscosity are the most influencing parameters. 
There may be a significant loss of the product during spray drying, 
due to adhesion of the microparticles to the inner wall of the spray-drier 
apparatus, or to agglomeration of the microparticles. To solve these 
problems, a novel technique has been developed; using two injection 
devices and mannitol as an antiadherent. A polymer–drug solution was 
sprayed through one nozzle and simultaneously an aqueous mannitol 
solution was sprayed through the second nozzle. The resulting microspheres 
exhibited surfaces coated with mannitol that decreased agglomeration. 
The use of a novel low-temperature spraying method has been 
reported by the company Alkermes (ProLease technology) for preparing 
PLA and DL-PLGA microspheres. A powder composed of protein (human 
growth hormone) and stabilizing excipients was suspended in a solution of 
polymer in acetone, ethyl acetate, or DCM. This suspension was then 
sprayed into a vessel containing liquid nitrogen. The liquid nitrogen was 
then evaporated and the organic solvent of the frozen droplets was extracted 
by liquid ethanol. Microspheres were then filtered and vacuum dried to 
eliminate residual solvents. The microspheres were 50 to 60 mm in size with 
drug encapsulation efficiency higher than 95%. 
Contrary to coacervation and emulsification methods, the spray 
drying method is a one-step quick process, and is continuous, easy to scale-
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up, and inexpensive. It is less dependent on the solubility parameters of the 
drug and the polymer, and can be used without organic solvents. When used 
with organic solvents, the amount of residual solvent in particles is often 
lower than that reached with emulsification–solvent removal techniques 
(0.05–0.2%). They can, however, be higher than the limit value of the 
Pharmacopoeia (0.06% for DCM). Nevertheless, a solvent less toxic than 
DCM, such as ethyl formate, has been widely used 
Spray drying is defined as the transformation of a feed from a fluid 
state (solution, dispersion, or paste) into a dried particulate form by spraying 
the feed into a hot gaseous drying medium (fig., 1.2). It is a continuous one-
step processing operation in which four different phases can be 
distinguished, namely: 
1. Atomization of the feed, 
2. Mixing of spray and air, 
3. Solvent evaporation, and 
4. Product separation. 
A variety of atomization systems are available, which may be 
classified according to the nozzle design as rotary atomization, pressure 
atomization, and two-fluid atomization: 
1. In rotary atomization, the feed fluid is sprayed into the drying 
chamber by means of a spinning disc or wheel which creates a spray of 
droplets. 
2. Pressure atomization occurs when the feed is fed to the nozzle under 
pressure which causes the fluid to be disrupted into droplets. 
3. In two-fluid nozzles, the feed fluid and atomizing air are passed 
separately to the nozzle, where they mix, and the air causes the feed to 
break up into a spray (Benita, 2006). 
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Figure 1.2  Laboratory spray dryer: (1) drying air inlet filtration; (2) heating; (3) 
desiccation chamber; (4) cyclone; (5) collector for drying powder-microspheres; 
(6) filtration air outlet; (A) solution, suspension, emulsion to spray; (B) 
compressed or nitrogen air; and (C) spray nozzle (e.g., pneumatic, ultrasonic) 
(Benita, 2006) 
 
The selection of the atomizer affects directly the desired particle 
size. Rotating disks can be used with very viscous feeds, and hence allow 
for the formation of microspheres up to 200 µm. Two-fluid nozzle atomizers 
with nozzles of a typical internal diameter between 0.5 and 1.0 mm, lead 
usually to small microparticles with a diameter less than 10 µm. 
Two different spray dryer designs can be distinguished. If spray and 
drying air pass through the dryer in the same direction, they operate in a 
concurrent manner. If spray and drying air enter the drying chamber at 
opposite ends, they operate in a counter-current fashion. The latter design is 
preferred when ‘‘sticky’’ products such as microspheres from polymers with 
low glass transition temperatures need to be processed. Because of the rapid 
evaporation of the solvent, the temperature of the droplets can be kept far 
below the drying air temperature, and is therefore applicable to both heat-
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resistant and heat-sensitive materials. For environmental protection, closed 
loop systems with recovery of the evaporated solvents are commercially 
available. Also, spray drying in an atmosphere of inert gas or under aseptic 
conditions is technically feasible (Benita, 2006). 
 
1.1.2.4.1 Material used in spray drying microencapsulation 
 
A. Polymethacrylates: 
Polymethacrylates (Methacrylic acid copolymer) is defined in United 
States Pharmacopoeia as a fully polymerized copolymer of methacrylic acid 
and an acrylic or methacrylic ester (USP30-NF25, 2007). 
Polymethacrylates are synthetic cationic and anionic polymers of 
dimethylaminoethylmethacrylates, methacrylic acid, and methacrylic acid 
esters in varying ratios. Several different types are commercially available 
and may be obtained as the dry powder, an aqueous dispersion, or as an 
organic solution. 
Polymethacrylates are primarily used in oral capsule and tablet 
formulations as film-coating agents. Depending on the types of polymer 
used, films of different solubility characteristics can be produced. 
Basic Butylated Methacrylate Copolymer (Eudragit E) is used as a plain 
or insulating film former; it is soluble in gastric fluid below pH 5. In 
contrast, Eudragit L and S types are used as enteric coating agents since they 
are resistant to gastric fluid. 
Eudragit RL, RS, and NE 30 D are used to form water-insoluble film 
coats for sustained-release products  
Polymethacrylates are also used as binders in both aqueous and organic 
wet granulation processes. They may additionally be used to form the matrix 
layers of transdermal delivery systems (Rowe et al, 2006). 
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B. Basic Butylated Methacrylate Copolymer (Eudragit E) 
Butylated Methacrylate Copolymer is a copolymer of 2-
(dimethylamino)ethyl methacrylate, butyl methacrylate and methyl  
methacrylate having a mean relative molecular mass of about 150 000. The 
ratio of 2- dimethylaminoethyl methacrylate groups to butyl methacrylate 
and methyl  methacrylate groups is about 2:1:1. 
It is colorless or yellowish granules or white powder, slightly hygroscopic. 
(British Pharmacopoeia, 2008) 
Eudragit E is cationic polymer based on dimethylaminoethyl 
methacrylate and other neutral methacrylic acid esters. It is soluble in gastric 
fluid as well as in weekly acidic buffer solutions (up to approximately pH 
5).Eudragit E is available as a 12.5% ready to use solution in propan-2-
ol/acetone (60:40). It is light yellow in color with the characteristic odor of 
the solvents. Solvent-free granules contain more or equel to 98% dried 
weight content of Eudragit E (Rowe et al 2006). 
 
 
C. Ethylcellulose 
Ethylcellulose with complete ethoxyl substitution is 
C12H23O6(C12H22O5)nC12H23O5 where n can vary to provide a wide variety of 
molecular weights. Ethylcellulose, an ethyl ether of cellulose, is a long-
chain polymer of β-anhydroglucose units joined together by acetal linkages. 
It is a tasteless, free-flowing, white to light tan-colored powder 
Structural Formula 
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It can be used as a coating agent, flavoring fixative, tablet binder;, 
tablet filler or viscosity-increasing agent. 
Ethylcellulose is widely used in oral and topical pharmaceutical 
formulations. The main use of ethylcellulose in oral formulations is as a 
hydrophobic coating agent for tablets and granules. Ethylcellulose coatings 
are used to modify the release of a drug, to mask an unpleasant taste, or to 
improve the stability of a formulation; for example, where granules are 
coated with ethylcellulose to inhibit oxidation. Modified-release tablet 
formulations may also be produced using ethylcellulose as a matrix former.  
Ethylcellulose, dissolved in an organic solvent or solvent mixture, can 
be used on its own to produce water-insoluble films. Higher-viscosity 
ethylcellulose grades tend to produce stronger and more durable films. 
Ethylcellulose films may be modified to alter their solubility, by the addition 
of hypromellose or a plasticizer. An aqueous polymer dispersion (or latex) 
of ethylcellulose such as Aquacoat ECD (FMC Biopolymer) or Surelease 
(Colorcon) may also be used to produce ethylcellulose films without the 
need for organic solvents. (Rowe et al, 2006) 
Drug release through ethylcellulose-coated dosage forms can be 
controlled by diffusion through the film coating. This can be a slow process 
unless a large surface area (e.g. pellets or granules compared with tablets) is 
utilized. In those instances, aqueous ethylcellulose dispersions are generally 
used to coat granules or pellets. Ethylcellulose-coated beads and granules 
have also demonstrated the ability to absorb pressure and hence protect the 
coating from fracture during compression.  
High-viscosity grades of ethylcellulose are used in drug 
microencapsulation.  Release of a drug from an ethylcellulose microcapsule 
is a function of the microcapsule wall thickness and surface area. 
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In tablet formulations, ethylcellulose may additionally be employed 
as a binder, the ethylcellulose being blended dry or wet-granulated with a 
solvent such as ethanol (95%). Ethylcellulose produces hard tablets with low 
friability, although they may demonstrate poor dissolution. 
Ethylcellulose has also been used as an agent for delivering therapeutic 
agents from oral (e.g. dental) appliances. In addition, ethylcellulose is used 
as a thickening agent in creams, lotions, or gels, provided an appropriate 
solvent is used. Ethylcellulose has been studied as a stabilizer for emulsions. 
(Rowe et al, 2006) 
D. Shellac 
Shellac is a naturally occurring material that may be obtained in a 
variety of refined or modified forms. Generally, shellac occurs as hard, 
brittle, transparent, pale lemon-yellow to brownish orange-colored flakes of 
varying size and shape; it is also available as a powder. Shellac is tasteless 
and odorless, or may have a faint odor 
Shellac has been used in pharmaceutical formulations for the enteric coating 
of tablets and beads, the material usually being applied as a 35% w/v 
alcoholic solution. It is a primary ingredient of pharmaceutical printing inks 
for monogramming capsules and tablets, and can be applied as a 40% w/v 
alcoholic solution. It has also been used to apply one or two sealing coats to 
tablet cores to protect them from moisture before being film- or sugar 
coated. Shellac may also be used in food products and cosmetics 
After long periods of storage, shellac becomes less readily soluble in 
alcohol, less fluid on heating, and darker in color. Shellac-coated tablets 
may have increased disintegration times following prolonged storage owing 
to changes in the physical characteristics of the coating (Rowe et al, 2006). 
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E. Glyceryl monostearate 
Glyceryl monostearate is a white to cream-colored, waxlike solid in 
the form of beads, flakes, or powder. It is waxy to the touch and has a slight 
fatty odor and taste. 
The many varieties of glyceryl monostearate are used as nonionic 
emulsifiers, stabilizers, emollients, and plasticizers in a variety of food, 
pharmaceutical, and cosmetic applications. It acts as an effective stabilizer, 
that is, as a mutual solvent for polar and nonpolar compounds that may form 
water-in-oil or oil-in-water emulsions. These properties also make it useful 
as a dispersing agent for pigments in oils or solids in fats, or as a solvent for 
phospholipids, such as lecithin. Glyceryl monostearate has also been used in 
a novel fluidized hot-melt granulation technique for the production of 
granules and tablets. 
Glyceryl monostearate is a lubricant for tablet manufacturing and 
may be used to form sustained-release matrices for solid dosage forms. 
Sustained-release applications include the formulation of pellets for tablets 
or suppositories and the preparation of a veterinary bolus. Glyceryl 
monostearate has also been used as a matrix ingredient for a biodegradable, 
implantable, controlled-release dosage form. 
When using glyceryl monostearate in a formulation, the possibility of 
polymorph formation should be considered. The α-form is dispersible and 
foamy, useful as an emulsifying agent or preservative. The denser, more 
stable, β-form is suitable for wax matrices. This application has been used to 
mask the flavor of clarithromycin in a pediatric formulation (Rowe et al, 
2006). 
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F. Acetone  
Acetone is a colorless volatile, flammable, transparent liquid, with a 
sweetish odor and pungent sweetish taste. It is dimethylformaldehyde; 
dimethyl ketone; β-ketopropane; pyroacetic ether. Its chemical name is 2-
propanone and its empirical formula and molecular weight are C3H6O and 
58.08 gm, respectively. 
Structural Formula: 
 
Acetone is used as a solvent or cosolvent in topical preparations, and 
as an aid in wet granulation. It has also been used when formulating tablets 
with water-sensitive active ingredients, or to solvate poorly water-soluble 
binders in a wet granulation process. Acetone has also been used in the 
formulation of microspheres to enhance drug release. Owing to its low 
boiling point, acetone has been used to extract thermolabile substances from 
crude drugs (Rowe et al, 2006). 
 
G. Dichloromeathane 
Dichloromethane is a clear, colourless, volatile liquid, sparingly 
soluble in water, miscible with alcohol (British pharmacopoeia, 2008). 
Dichloromethane is used as a pharmaceutical and industrial solvent. It is 
also employed as an extraction solvent in food processing. Additionally it is 
widely used in paint strippers (Rowe et al, 2006). 
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1.2. Literature review 
1.2.1. Clavulanic acid: 
It has been mentioned by Saudagar et al (2008) that clavulanic 
acid is a major β-lactam antibiotic and was discovered independently by 
Brown et al. (1976) and Napier et al. (1981) as a product of the organism 
Streptomyces clavuligerus. Streptomyces clavuligerus had been isolated in 
1971 in a screening programme for producers of β-lactam compounds with 
improved resistance to β-lactamases (Nagarajan et al., 1971). 
1.2.1 Stability of Clavulanic acid 
Jeon et al (2004) prepared microencapsulated potassium clavulanate 
to enhance its stability during storage conditions. The microencapsulated 
particles containing potassium clavulanate were prepared by spray drying 
method or hot melting method, respectively. Dextrin, sucrose and 
polyvinylpyrrolidone were used as coating materials. A mixture of drug, 
coating material, sodium lauryl sulfate and Aerosil 200 were uniformly 
dispersed in water and then spray-dried at 70°C with a flow rate of 15 
ml/min. On the other hand, drug was uniformly added into melted carnauba 
wax at 80ºC and then cooled at a refrigerator. The solid mass was then 
milled into particles. The resulting microencapsulated particles containing 
potassium clavulanate were stored in light-protected sealed glass bottles at 
refrigerator, room temperature and 40°C/ R.H.75% temperature equilibrium 
chamber, respectively. The physical properties and drug contents were then 
evaluated as a function of time. 
The microencapsulated spray-dried particles were successfully 
obtained. Dextrin gave good powdered flow properties. However, the 
appearance of color gradually changed into yellow. Drug contents also 
decreased during storage condition due to water remaining in 
microencapsulated spray-dried particles. The solvents for spray drying could 
be carefully considered. The microencapsulated particles by hot-melting 
method using carnauba wax gave good physical properties as well as 
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enhanced chemical stability. The wax-based particles were more stable 
when dispersed in aqueous phase but the stability gradually decreased over 
extended storage periods. They concluded that the microencapsulation of 
potassium clavulanate using wall materials may provide a way to enhance 
stability during storage condition. The microencapsulated potassium 
clavulanate could be used as reconstitution dosage forms. 
Bersanetti and coworkers (2005) investigated CA degradation rate 
from various sources at temperatures of 10, 20, 25, 30 and 40 ◦C and pH 
values of 6.2 and 7.0. The results showed that first-order kinetics explained 
very well the hydrolysis kinetics and the Arrhenius equation could be 
applied to establish a relationship between the degradation rate constant and 
temperature, at both pHs. It has been observed that CA from fermentation 
medium was much more unstable than that from standard solution and from 
a commercially available medicine. Also, it was observed that CA was more 
stable at pH 6.2 than at pH 7.0, irrespective of the CA source. 
A study for the evaluation of CA long-term stability under different 
conditions of pH and temperature, in the presence of variable levels of 
different salts was recently published (Santos et al, 2009). The aim of the 
study was to suggest the best conditions to perform its simultaneous 
production and recovery by two-phase polymer/salt liquid–liquid extractive 
fermentation. The CA stability was investigated at different values of pH 
(4.0–8.0) and temperature (20–45°C), and the best conditions were met at a 
pH 6.0–7.2 and 20°C. Its stability was also investigated at 30°C in the 
presence of NaCl, Na2SO4, CaCl2 and MgSO4 at concentrations of 0.1 and 
0.5M in Mcllvaine buffer (pH 6.5). All salts led to increased CA instability 
with respect to the buffer alone, and this effect decreased in following 
sequence: Na2SO4 > MgSO4 > CaCl2 > NaCl. Kinetic and thermodynamic 
parameters of CA degradation were calculated adopting a new model that 
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took into consideration the equilibrium between the active and a reversibly 
inactivated form of CA after long-time degradation. 
1.2.2 Microencapsulation by spray drying. 
Zgoulli et al (1998) investigated the feasibility of a one-step spray-
drying process to microencapsulate erythromycin and clarithromycin, 
antibiotics known to have an unpleasant, bitter taste. Mixtures of 
clarithromycin (5% by weight) or erythromycin (30% by weight) with a 
biodegradable polymer were prepared and spray-dried under specific 
conditions of temperature and turbine speed. This process resulted in the 
microencapsulation of 80% of each drug as determined by high pressure 
liquid chromatography. Particle size ranged from 1 to 80 mm as determined 
by electron microscopy. These data showed that microencapsulation of 
macrolides using a spray-drying technique is feasible and might be useful in 
the formulation of palatable oral suspensions of bitter tasting drugs. 
A comparative investigation of the characteristics of ascorbic acid 
microcapsules prepared by different methods, such as thermal phase 
separation, melt dispersion, solvent evaporation and spray drying was 
carried out by Uddin et al (2001). Scanning electron microscopy (SEM), 
release tests and size distribution were used for the evaluation of product 
characteristics. Their results showed that microencapsulated ascorbic acid 
could prevent the ascorbic acid colour change, retard its core release rate, 
and generally mask its acid taste. In the thermal phase separation, molecular 
weight (Mw) of ethyl cellulose (EC) and the addition of polyisobutylene 
(PIB) significantly influenced the aggregation and release rate of 
microcapsules. In the melt dispersion method, spherical particles were 
prepared by using carnauba. The ascorbic acid release rate was found to be 
slower in the case of carnauba-encapsulated ascorbic acid than that made by 
EC using other methods. In the solvent evaporation method, a higher Mw of 
EC and the addition of plasticizer were also found to be important for good 
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encapsulation. In the spray drying method, loss of ascorbic acid was found 
to be the minimum during microencapsulation. Starch and beta-cyclodextrin 
encapsulated ascorbic acid delayed the degradation of ascorbic acid during 
storage at 38°C and relative humidity 84.0%. 
Martinac et al (2005) carried out a study to develop spray-dried 
chitosan-basedmicrospheres, suitable for nasal delivery of loratadine, and to 
evaluate their potential of modifying loratadine release. The microspheres 
were composed with ethylcellulose (EC) and chitosan (CM) in two different 
weight ratios, 1:2 and 1:3. One-phase systems (dispersions) and two-phase 
systems (emulsions and suspensions) were subjected to spray-drying, 
resulting in conventional and composed microspheres, respectively. The 
microspheres were evaluated with respect to the yield, particle size, 
encapsulation efficiency, physical state of the drug in the polymer matrix, 
swelling properties and in vitro drug release profile. It was shown that 
particle size, swelling ability and loratadine release from spray-dried 
microspheres were significantly affected by the polymeric composition and 
feed concentration in spray-drying process. Emulsifying method to produce 
composed EC/CM microspheres resulted in improved loratadine entrapment 
and moderate swelling, when compared to conventional chitosan 
microspheres. It seems like better formation of EC cores and chitosan 
coating were obtained when higher feed concentration and ultrasonic 
homogenization were employed in the preparation of emulsion systems and 
when EC to CM weight ratio was 1:3. 
In another study solid state stability of microencapsulated protein 
drug was evaluated (Gayakwad et al, 2005). Lysozyme as a model protein 
drug has been microencapsulated by spray drying technique. Microspheres 
were prepared with Bovine Serum Albumin (BSA) as a matrix. All 
experimental parameters were optimized. The mean particle size and zeta 
potential was determined using a Malvern Zetasizer. Effect of formulation 
processing on the secondary structure of lysozyme was studied using Perkin 
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Elmer Fourier transformed infrared spectroscopy (FTIR) and differential 
scanning calorimetry (DSC). The mean microsphere particle size was 103.3 
± 2.9 nm and the zeta potential was found to be -23.47 ± 3.96 mV at pH 5.8. 
FTIR spectra for the lysozyme before and after encapsulation into albumin 
microspheres showed similar absorption bands at 1650 1cm −  and 1540 1cm −  
characteristic of the amide I and amide II bands of lysozyme. DSC 
thermograms of the microencapsulated lysozyme contained an endotherm 
corresponding to lysozyme melting/denaturation peak. The melting 
temperature Tm was found to be 214ºC ± 10ºC as compared to the Tm value 
of 74º0 C for lysozyme in solution at pH 4.0 in 50 mM citrate buffer. The 
zeta potential for the microencapsulated lysozyme showed that the 
microspheres have good suspension stability at pH 5.8. FTIR analysis before 
and after the microencapsulation using the spray drying process 
demonstrates that the lysozyme secondary structure is not affected by the 
spray drying conditions. A high Tm value for microencapsulated lysozyme 
showed that the native structure of the enzyme is maintained after the spray 
drying process and is further stabilized by the microsphere matrix. The 
study concluded that the formulation conditions used have no significant 
negative effect on the native structure of the enzyme. 
Ozeki et al (2006) used a 4-fluid nozzle spray drier to prepare 
polymeric submicron particle-containing microparticles. Ethylcellulose (EC) 
and poly(lactic-co-glycolic acid) (PLGA), either alone or in combination 
with polyethylenimine (PEI), were used as polymers to produce submicron 
particles, and mannitol (MAN) was used as a water-soluble carrier for the 
microparticles. The polymer and MAN solutions were supplied through 
different liquid passages of a 4-fluid nozzle and then dried to obtain MAN 
microparticles containing EC or PLGA submicron particles. The 
polymer/MAN ratio was controlled by changing the concentration of the 
polymer and MAN solutions. EC or PLGA microparticles were observed via 
32 
(SEM) and the size of microparticles was determined by image analysis. 
The particle size distribution of EC or PLGA submicron particles was 
measured with a super dynamic light scattering spectrophotometer. The 
method generated submicron-sized (<1 microm) particles of EC and PLGA. 
The mean diameters of EC and PLGA particles at a polymer/MAN ratio of 
1:10 were 631 and 490 nm, respectively. The mean diameter of PLGA 
particles decreased as the PLGA/MAN ratio was reduced, reaching 
approximately 200 nm at a PLGA/MAN ratio of 1:100. The mean diameter 
of PLGA/PEI particles at PLGA/PEI/MAN ratios of 1:0.5:10 and 1:0.5:100 
were 525 and 223 nm, respectively, and their zeta potentials were +50.8 and 
+58.2 mV, respectively. The size of EC submicron particles could be 
controlled by varying the spray conditions. This study demonstrated that it is 
possible to prepare polymeric submicron particles dispersed in MAN 
microparticles in a single process using the 4-fluid nozzle spray drying 
method. Cationic PLGA particles with a diameter of approximately 200 nm 
could be prepared by adding PEI, suggesting the possibility of its use as a 
carrier for delivering DNA into cells. The precipitation of EC may occur by 
the mutual dispersion and mixing of solvents after collision of EC and MAN 
mists by antisolvent effect, thereby producing MAN microparticles  
An experimental study of spray drying was carried out aimed at 
improvement of the phospholipid microencapsulation process. Three kinds 
of wall materials, maltodextrin blended with sodium caseinate, gelatin, and 
soy protein, respectively, were used to prepare phospholipid emulsion. 
Through examining the emulsion stability, a stable emulsion with the 
sodium caseinate contained system was obtained under 2.5 of mass ratio 
between maltodextrin and sodium caseinate, 70-80°C of emulsification 
temperature, 2.5% of emulsifier concentration, and 40 MPa of 
homogenization pressure. Phospholipid microcapsules with a mean size of 
62 µm in apparent geometric diameter and good fluidity, dispersion, and 
dissolubility were prepared under 140°C of air inlet temperature, 30°C of 
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feed temperature, and 20% of solids concentration up to 90% of 
phospholipids (Yu et al 2007). 
Cortesi R et al, (2007) described the production and characterization 
of polyacrylic polymer (Eudragit RL, RS and NE) microparticles by spray 
drying method. Microparticles were designed for ophthalmic administration 
of acyclovir. Microparticle morphology was characterized by optical and 
electron microscopy. The release kinetics of the drug from microspheres 
was determined by a dialysis method. The spray drying method described 
allows the production of microparticles with acceptable encapsulation 
efficiency and appropriate dimensional characteristics for ophthalmic 
administration. They found that release profile data indicate that acyclovir is 
released from microparticles in a controlled manner. In addition the release 
pattern of the drug is influenced by the type of Eudragit used for 
microparticle production. Moreover the plaque reduction efficiency of 
acyclovir containing microparticles (except for RS/NE microspheres) is 
comparable to that displayed by the free drug. Their results suggested that 
acyclovir containing microparticles could represent an interesting system for 
the release of this antiviral drug at the eye site. 
Pantoprazole -loaded microparticles have been prepared by Raffin 
and his coworkers, (2007). The microparticles were prepared by spray-
drying using a blend of Eudragit S100 and hydroxy propyl methyl cellulose 
(HPMC), which can provide gastro-resistance and controlled release. 
Microparticles presented acceptable drug loading (120.4 mg), encapsulation 
efficiency (92.3%), surface area (49.0 gm 2 ), and particle size (11.3 µ). DSC 
analyses showed that the drug is molecularly dispersed in the microparticles, 
and in vivo anti-ulcer evaluation demonstrated that microparticles were 
effective in protecting stomach against ulceration. Microparticles were 
successfully tabletted using magnesium stearate. In vitro gastro-resistance 
study showed that microparticles stabilized pantoprazole in 62.0% and 
tablets in 97.5% and provided a controlled release of the drug. 
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A study has been presented by Piao et al (2008) using spray-drying 
technique to develop a piroxicam-loaded gelatin microcapsule with 
enhanced bioavailability. A gelatin microcapsule encapsulated ethanol and 
piroxicam has been formulated by using gelatin as a water-soluble polymer 
shell. The aqueous solubility and bioavailability of piroxicam in piroxicam-
loaded microcapsule in rats were then evaluated compared to piroxicam 
powder. The piroxicam-loaded gelatin microcapsule spherical in shape with 
smooth surface showed the geometric mean diameter of about 19 micron. It 
had the piroxicam solubility of about 1.87 mg/ml and the amount of ethanol 
of about 4.37 µgm/mg. Furthermore, it gave significantly higher total 
plasma concentrations, maxC  and area under the blood concentration-time 
curve (AUC) of piroxicam in rats than did piroxicam powder, indicating that 
the drug from gelatin microcapsule could be more orally absorbed in rats. In 
particular, the AUC of piroxicam in gelatin microcapsule was significantly 
about 2 fold increased compared to piroxicam powder. This enhanced oral 
relative bioavailability of piroxicam in gelatin microcapsule was contributed 
by the marked increase in the absorption rate of piroxicam due to the 
improved solubility of piroxicam. The study suggested that piroxicam-
loaded gelatin microcapsule developed using spray-drying technique with 
gelatin, sodium lauryl sulfate and ethanol would be useful to deliver 
piroxicam in a pattern that allows fast absorption in the initial phase, leading 
to better absorption. 
PLGA microparticles encapsulating therapeutic proteins were 
prepared by Mok and Park, (2008) under a water-free formulation condition. 
Bovine serum albumin (BSA) and recombinant human growth hormone 
(rhGH) were homogeneously solubilized as nano-scale complexes in 
methylene chloride phase by using polyethylene glycol (PEG) as a complex-
forming agent. The organic phase containing dissolved PLGA and 
PEG/protein complexes was directly spray dried to obtain PLGA 
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microparticles encapsulating proteins. They exhibited sustained release 
profiles of BSA and rhGH up to 30 days with reduced initial bursts. The 
released protein molecules from the microparticles maintained structural 
integrity without aggregation, suggesting that the current single-step protein 
microencapsulation method without using water could be potentially applied 
for sustained delivery of a wide range of therapeutic protein drugs that are 
not soluble in organic solvents. 
Spry drying method has been used by Zhang et al, (2008) for the 
preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) 
loaded with 10-hydroxycamptothecin. Hydroxycamptothecin (HCPT) 
loaded polyethylene glycol (PEG) modified NLC (PEG-NLC) was prepared 
by high pressure homogenization and spray drying method. PEG-NLC 
showed spherical particle with smooth surface in SEM analysis. The 
crystallinity of lipid matrix within PEG-NLC was evaluated by powder X-
ray diffraction and differential DSC. The less ordered crystals or amorphous 
state of matrix were found in nanoparticles. A small, homogeneous particle 
size and high drug loading with fine entrapment efficiency of HCPT was 
obtained in PEG-NLC system. HCPT releasing from PEG-NLC showed a 
sustained release trend, and no significant difference was found between two 
release curves of PEG-NLC before or after spray drying. After storage for 6 
months, PEG-NLC powder after spray drying showed no significant 
changes in particle size, drug loading and entrapment efficiency, crystal 
form and in vitro release. PEG modification statistically decreased the 
phagocytosis of NLC by RAW 264.7 cells, and spray drying process did not 
influence the cellular uptake of PEG-NLC. They suggested that PEG-NLC 
prepared by spray drying is a stable and high-performance delivery system 
for HCPT. 
Nassar T et al, (2008) carried out a study to develop a double-coated 
nanoparticulate delivery system of tacrolimus capable of overcoming the P-
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glycoprotein pump and CYP3A barriers without affecting their 
physiological activities. Tacrolimus loaded oil cores were first 
nanoencapsulated with two polymethacrylate polymers followed by the 
microencapsulation of these nanocapsules within hydroxyl propyl 
methylcellulose using a spray drying technique. The Trojan effect of these 
double-coated nanocapsules was evaluated in Caco-2 monolayer by 
monitoring the tacrolimus uptake and measuring the transport of tacrolimus 
across the rat jejunum membrane. The formulation was shown to release 
nanocapsules rather than dissolved drug under sink conditions. The 
nanocapsules protected tacrolimus from degradation in the diluted intestinal 
fluids following 2 h incubation. The Caco-2 and intestinal segment uptake 
of tacrolimus from the novel delivery system with and without verapamil 
was significantly higher than the uptake of tacrolimus from the aqueous 
solution and emulsion. The blank drug delivery system did not inhibit the P-
gp pump activity. The nanocapsules internalized rapidly in the enterocytes 
as confirmed by the histological results. The novel nanodelivery system 
which does not alter the activity of the P-gp is suggested as a potential 
platform for intestinal transport of sensitive lipophilic molecules that are P-
gp substrates. 
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1.2.3 Materials used in spray drying microencapsulation 
A. Polymethacrylates: 
As has been previously mentioned, Cortesi et al (2007) described 
the production and characterization of polyacrylic polymer (Eudragit RL, 
RS and NE) microparticles by spray drying method.  
B.Basic Butalyted Methacrylate Copolymer (Eudragit E) 
Eudragit E was used to reduce the bitterness with improved 
dissolution, in acidic medium (pH 1.2), of mefloquine hydrochloride (MFL). 
Microparticles were prepared by coacervation method using Eudragit E (EE) 
as polymer and sodium hydroxide as precipitant Mi (Shah et al, 2008). 
C. Ethyl Cellulose  
Shi and Tan (2002) investigated a system consisting of chitosan (CS) 
microcores entrapped within enteric polymer. Vitamin D2 (VD2), used as a 
model drug, was efficiently entrapped in CS microcores using spray drying 
and was microencapsulated by coating with ethylcellulose. The morphology 
and release properties of microcapsules were tested. The factors which 
influenced the preparation, including molecular weight of CS, concentration 
of CS solution, concentration of acetic acid and loading of VD2, were 
discussed. The results of release in vitro showed that the microcapsules 
could realize sustained release in intestine juice. 
Ethylcellulose and chitosan were used by Hafner et al (2007) in the 
development and in vitro characterization of chitosan-based microspheres 
for nasal delivery of promethazine. Conventional and composed 
promethazine-loaded microspheres were prepared by spray drying of 
chitosan solution systems and double water-in-oil-in-water (W/O/W) 
emulsion systems, respectively. Double emulsions were prepared in two 
different feed concentrations, with chitosan dissolved in both water phases, 
and ethylcellulose dissolved in oil phase. Swelling and bioadhesive 
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properties of the microspheres depended on the chitosan content, type and 
the feed concentration of spray-dried system. Results obtained suggested 
that better ethylcellulose microcapsules with promethazine in the chitosan 
matrix were formed when less concentrated emulsion systems were spray-
dried. Thus, in case of such a system, with ethylcellulose/chitosan weight 
ratio of 1:2, prolonged promethazine release was obtained. 
D. Acetone 
Acetone, as a solvent, was used by Bain et al (1999) to study the 
influence of different solvents on spray-dried biodegradable microspheres. 
Microspheres of fixed poly D,L-lactic acid (PDLLA) composition Resomer 
R104:R202H (30:70) containing 20% w/w rifampicin have been spray-dried 
from a range of acetonic, halogenated, and solvent mixtures thereof under 
constant process conditions to examine the influence of solvent selection on 
microsphere characteristics. It was observed that solubility of the polymer 
composite in the studied solvents determined the kinetics of polymer 
deposition during drying. Viscosity studies provided an indirect index of 
solvent power in ascending order: acetone (ACT) < dichloromethane (DCM) 
< chloroform (CFM) < halothane (HAL). Accordingly, poorer acetonic 
solvents produced a more open, porous matrix of increased mean diameter, 
whereas DCM, CFM and HAL generated more coherent matrices of greater 
density and elevated glass transition temperature, which significantly 
retarded drug release. It was concluded that solvent choice for spray-drying 
has a remarkable influence on microsphere characteristics and, accordingly, 
technological as well as toxicological considerations should be paid during 
selection of the same. 
E.Dichloromethane 
As previously mentioned Mok and Park (2008) used 
dichloromethane (methylene chloride) in the microencapsulation of proteins. 
2. AIMS AND OBJECTIVES 
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2.1 Aims  
Microencapsulation of potassium clavulanate powder using a suitable 
coating polymer to increase the drug stability against moisture as well as 
against water when reconstituted. 
2.2 Objectives: 
• Selection of the most compatible solvents  
• Selection of the most suitable coating polymer 
• Selection of proper drug : coat ratio using the spray dryer 
• Carrying out the necessary tests to evaluate the coated drug. 
• Scale up of the selected formulae to a larger batch 
• Subject the prepared formulae to stability study at ambient 
temperature when reconstituted with water. 
• Subject the prepared formulae to stability study according to WHO 
guidelines. 
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3. EXPREMENTAL 
 
3.1 Materials and instruments  
 
3.1.1 Materials: 
The materials and their sources used in the study are summarized in 
table 3.1. 
Table 3.1 materials and their sources 
No. Material name Company Country 
1 Acetone (Analytical  reagent ) BDH England 
2 Chloroform(Analytical reagent ) BDH England 
3 Dichloromethane (Analytical reagent ) BDH England 
4 Diethyl ether(Analytical reagent ) BDH England 
5 Ethyl cellulose (Ethocel 20) Dow USA 
6 Eudragit E 100 Degussa Germany 
7 Glycerylmonostearate NBZ India 
12 Isopropyl alcohol Merk India 
8 Lithium clavulanate standard material CKD Bio Korea 
9 Methanol (analytical reagent) BDH England 
10 Methanol HPLC grade Acros Belgium 
11 Potassium clavulanate + Silicon dioxide (1 :1) CKD Bio Korea 
13 Shellac NBZ India 
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3.1.2. Instruments: 
Instruments and their sources used in the study are summarized in 
table 3.2. 
Table 3.2 instruments  and their sources 
# Instrument/Apparatus Model Manufacturer and country 
1 Analytical Balance HM-200 AND/Japan 
2 Balance (150 GM) TE153S Sartorius/Germany 
3 Dissolution apparatus DT70 Pharmatest/Germany 
4 
High performance Liquid 
Chromatography: 
1. Pump 
2. Uv-vis Detector 
3. Controller 
4. Column C18 
(Octadecyl silane) 
 
LC-10ADvp 
SPD-10Avp 
SCL-10Avp 
Hypersil 5µ 
(150mm*4.6 mm)
 
Shimadzu/Japan 
 
 
Thermo(Hypersil-
Keystone) 
5 Incubators( ovens) 200 Memmert/Germany 
6 Magnetic stirrer ARE VELP Scientifica /Eurpoe 
7 Mini Laboratory Spray dryer WPG-200 
Jinan Honor Energy 
Technology Co., 
Ltd/China 
8 pH meter pp-50 Sartorius/Germany 
9 Sonicator 1428 E intertech / India  
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3.2. Method  
3.2.1 Selection of the most compatible solvents: 
It is essential to predict the effect of each component on the drug. 
This will aid in the selection of the most compatible ingredient and to avoid 
any useless components. 
Fortunately, potassium clavulanate is hydrolyzed in water (or in the 
presence of moisture) giving yellow to red color, so detection of any 
instability or incompatibility will depend on the change of the color of 
potassium clavulanate, i.e. detection was done visually. 
Procedures: 
0.5 gm of potassium clavulanate was added to two ml of the solvent in a test 
tube. Solvents used are : water ( as a reference )- methanol – absolute 
ethanol – isopropyl alcohol – acetone – dichloromethane – chloroform – 
ether. The drug – solvent mixture was tested visually (compared with 
potassium clavulanate powder) daily for six days to detect any color change. 
 
3.2.2: Selection of the most suitable coating polymer: 
Coating polymers used are ethylcellulose, eudragit E, 
glycerylmonostearate and shellac. 
Solvents used are ether, chloroform, acetone and dichloromethane 
Procedures: 
0.5 gm of each polymer was transferred into a test tube containing 5 ml of 
the solvent. The mixture is agitated and clarity of the mixture was detected 
viually. 
Solubility of coating polymers in different solvents was tested as 
well as the physical properties of each coating polymer. Detection was done 
visually. Accordingly the most suitable polymer and solvent were selected 
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3.2.3 Selection of proper ratio between potassium clavulanate and the coating 
material using the spray dryer 
A total of 11 experiments were carried out to select the appropriate 
ratio between potassium clavulanate (PC) and coating material (Eudragit 
E).the experiment varied in ambient temperature and outlet temperature. 
These experiments are shown below: 
Exp. No. 1: 
Materials sued were potassium clavulanate/silicone dioxide anhydrous 
(PC/SiO2) mixture, Eudragit E and acetone. 
The ratio of PC mixture to the coat was 2:1. 
Procedures: 
• The spray dryer was adjusted according to the following parameters:  
Inlet Temperature Compressed air pressure Liquid flow rate 
45ºC 0.2 Mpas. 5ml/min. 
 
• Eudragit E (1 gm) was dissolved in Acetone (100 ml) in a conical 
flask 
• With continuous stirring, PC/SiO2 mixture (1 gm) was gradually 
added to the previous solution. 
• The mixture was spray dried through the spray dryer 
• The dried powder was collected in the cyclone collector  
• A known weighed quantity of the dried powder was placed in a test 
tube containing 5 ml of purified water. The test tube was shaken 
gently and labeled as T 
• An equivalent quantity of untreated PC/SiO2 was placed in a similar 
test tube containing 5 ml of purified water. The test tube was shaken 
gently and  labeled as S. 
• Both test tubes were daily checked visually to detect any color change  
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Experiment No. 2 
Same as Experiment No. 1 except that the PC/SiO2 to coat ratio was 1:1. 
 
Experiment No. 3 
Same as Experiment No. 1 except that the PC/SiO2 to coat ratio was 1:2 
 
Experiment No. 4 
Same as Experiment No. 1 except that the solvent used was chloroform and 
the PC/SiO2 to coat ratio was 2:1 
 
Experiment No. 5 
Same as Experiment No. 1 except that the solvent used was chloroform and 
the PC/SiO2 to coat ratio was 1:1 
 
Experiment No. 6 
Same as Experiment No. 1 except that the solvent used was chloroform and 
the PC/SiO2 to coat ratio was 1:2 
 
Experiment No. 7 
Same as Experiment No. 1 except that the solvent used was 
dichloromethane and the PC/SiO2 to coat ratio was 1:1 
 
Experiment No. 8 
Same as Experiment No. 1 except that the solvent used was 
dichloromethane and the PC/SiO2 to coat ratio was 1:2 
Experiment No. 9 
Same as Experiment No. 1 except that the solvent used was diethyl ether 
and the flow rate was increased to 6 ml/min. because the mixture was 
difficult to force through the spray dryer. PC/SiO2 to coat ratio was 2:1 
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Experiment No. 10 
Same as Experiment No. 1 except that the solvent used was diethyl ether 
and the flow rate was increased to 6 ml/min. because the mixture was 
difficult to force through the spray dryer. PC/SiO2 to coat ratio was 1:1. 
 
Experiment No. 11 
Same as Experiment No. 1 except that the solvent used was diethyl ether 
and the flow rate was increased to 6 ml/min. because the mixture was 
difficult to force through the spray dryer. PC/SiO2 to coat ratio was 1:2. 
3.2.4 Quality Control Test for the selected PC/SiO2 to coat ratio 
preparation 
PC/SiO2 to Eudragit E ratio 1:1 and acetone have been selected as 
the most suitable preparation. The experiment was repeated and subjected to 
the following quality control tests: 
3.2.4.1 Visual test to detect color change: 
A known weighed quantity of the dried powder was placed in a test tube 
containing 5 ml of purified water. The test tube was shaken gently and 
labeled as T. An equivalent quantity of untreated PC/SiO2 was placed in 
a similar test tube containing 5 ml of purified water. The test tube was 
shook gently and labeled as S 
Both test tubes were daily checked visually to detect any color change  
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3.2.4.2 Determination of Clavulanic acid content (Yield): 
For the determination of Clavulanic acid content (Yield), High 
Performance Liquid Chromatography (HPLC) method of analysis derived 
from The United States Pharmacopoeia (USP30-NF25) was used: 
Mobile phase preparation: 
Sodium phosphate buffer, pH 4.4, was prepared by dissolving 7.8 
gm of monobasic sodium phosphate in 900 ml of purified water. The pH 
was adjusted to 4.4 by 10 N NaOH. A mixture of pH 4.4 phosphate 
buffers and methanol (95:5) was prepared and passed through a 
membrane filter having 0.5 µ porosity. 
Adjustment of liquid chromatograph  
The liquid chromatograph was equipped with a 220-nm detector and 
a 4 mm × 15 cm column containing 5µm packing L1 (Octadecyl silane). 
The flow rate was 2 ml/min.  
Preparation of different standard solutions for a calibration curve 
A stock standard solution of lithium clavulanate having a 
concentration of 0.42 mg per ml (equivalent to 0.4 mg/ml of clavulanic 
acid) was prepared by dissolving lithium clavulanate (working standard) 
in water. 
From the stock solution, different standard solutions were prepared with the 
following concentrations: 0.5, 0.25, 0.125, 0.0625, 0.0313 and 0.0156 mg 
per ml. 
The calibration curve was drawn by plotting the concentration of 
each standard solution versus the respective peak response measured 
from the chromatograms. 
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Preparation of the sample solution for clavulanic acid content 
A quantity of the coated powder (500 mg containing the equivalent 
of 125 mg of potassium clavulanate which contains 105 mg of Clavulanic 
acid (note 1 mg of clavulanate (C8H9NO5) is equivalent to 1.191 mg of 
potassium clavulanate; C8H8KNO5. (British pharmacopoeia, 2008) was 
transferred into a 100 ml volumetric flask. About 5 ml of methanol HPLC 
grade were added to the flask and shook well to dissolve the coat as well as 
potassium clavulanate. The volume was completed to 100 ml with 
phosphate buffer (pH 4.4). The mixture was filtered through a filter paper. 
After that, 10 ml of the filtrate were accurately transferred into a 100 ml 
volumetric flask. Then the volume was completed to 100 ml with the mobile 
phase. The final theoretical concentration was 0.105 mg per ml of clavulanic 
acid. 
Procedures 
Equal volumes (about 20 µl) of standard and sample solutions were 
separately injected into the HPLC. Chromatograms were recorded and the 
peak responses were measured. Each sample was injected three times and 
their peak areas were summated and the average was calculated. The 
relative standard deviation of the repeated injections was calculated. 
The calibration curve was drawn by plotting the concentration of 
each standard solution versus the respective peak response measured from 
the chromatograms. 
The assay results were calculated according to the formulae: 
 
standard of areapeak 
ion)concentrat standardsample of area(peak contentCA ×=  
 
Yield (Y1) = (CA content / theoretical CA content in the sample) × 100 
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3.2.4.3 Determination of coating efficiency  
Preparation of the sample solution for coating efficiency 
A quantity of the coated powder 625 mg containing the equivalent of 
131.2 mg of clavulanic acid (based on the statement of British 
pharmacopoeia) was transferred into a 100 ml volumetric flask. About 30 ml 
of purified water were added and the mixture was gently shaken and the 
volume was completed to volume with water. The mixture was filtered and 
10 ml of the filtrate were accurately transferred to another 100 ml 
volumetric flask, the volume was completed with the mobile phase. The 
final theoretical concentration is 0.1312 mg/ml. 
Procedures 
Equal volumes (about 20 µl) of standard and sample solutions were 
separately injected into the chromatograph. Chromatograms were recorded 
and the peak responses were measured. Each sample was injected three 
times and their peak areas were summated and the average was calculated. 
The relative standard deviation of the repeated injections was calculated  
Clavulanic acid content was calculated according to the formulae: 
 
standard of areapeak 
ion)concentrat standardsample of area(peak contentCA ×=  
The yield of uncoated C.A (Y2)  
Y2 = (CA content / theoretical CA content in the sample) × 100 
Coating efficiency (C.E.) was calculated as follows: 
The ratio of uncoated PC to the total yield (R1) = (Y2/Y1)1×00 
Where: Y2 is the yield obtained from coating efficiency test. 
Y1 is yield obtained from CA determination test. 
R1 is the ratio of uncoated PC to the total yield 
Coating efficiency (CE) = 100 – R1 
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3.2.4.4 Determination of Drug release (Dissolution test) 
Since the coating material (Eudragit E).is insoluble in water and 
soluble in acidic media, it was preferred to carry out the drug release 
(dissolution) test in an acidic medium. The dissolution test method was 
obtained from the dissolution test mentioned in USP30-NF25 for 
amoxicillin and clavulanate potassium tablets except that the dissolution 
medium was changed to suit the current experiment: 
 
Preparation of dissolution media: 
Two different dissolution media were prepared; 0.1 M hydrochloric 
acid and phosphate buffer pH 3.5. 0.1 M Hydrochloric acid solution was 
prepared by diluting 100 ml of 1 M hydrochloric acid. The volume was 
diluted with water to 1000 ml. Phosphate buffer pH 3.5 was prepared by 
dissolving 68 g of potassium dihydrogen orthophosphate in 1000 ml of 
water and adjusting the pH of the solution to 3.5 with orthophosphoric acid. 
Three different dissolution vessels were filled with 900 ml. of each 
dissolution medium. Three types of samples were used; 0.500 gm of coated 
P.C (containing 105 mg of clavulanic acid), 0.250 gm of PC/SiO2 mixture 
(containing 105 mg of clavulanic acid) and Augmentin™ 625 mg tablets 
(containing 125 mg of clavulanic acid) 
 
Adjustment of the dissolution apparatus 
Buddle stirrers were fixed and rotation per minutes (rpm) was 
adjusted to 75 rpm. Time of dissolution was adjusted to 30 minutes. The 
temperature was adjusted to 37 ºC. 
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Procedures 
Each type of sample was separately placed in the two different 
dissolution media and the apparatus was started. A sample of 20 ml was 
withdrawn from each of the six vessels after 10, 20 and after 30 minutes. All 
samples were filtered and injected separately into the chromatogram 
mentioned in the coating efficiency test. 
Chromatograms were recorded and the peak responses were 
measured. The percentage of the dissolved or released drug was calculated 
according to the following: 
1. Calculation of the dissolved quantity of potassium clavulanate 
(Clavulanic acid) 
standard of areapeak 
ion)concentrat standardsample of area(peak dissolvedcontent CA ×=  
 
The percentage dissolved of CA 
= Content of dissolved CA ×100 / theoretical content added 
 
3.2.4.5 Microscopic examination of the coated PC/SiO2 using electron 
microscope. 
This test is usually done to detect the morphology and to measure the 
size of the coated particles. Unfortunately, this test was not performed 
because of the unavailability of electron microscope in Yemen and in 
Sudan. As an alternative way the particle size range of the microcapsules 
was determined using sieve no.200 (pore size is 63µ). About three gm of the 
coated PC/SiO2 powder were sieved through sieve no. 200 (pore size is 63µ) 
and the ratio of the passed quantity to the total quantity was determined. 
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3.2.5. Scale up of the selected solvent, coat and proper ratio  
Materials sued were potassium clavulanate/silicone dioxide anhydrous 
(PC/SiO2) mixture, Eudragit E and Acetone. 
The ratio of PC mixture to the coat was 1:1. 
Procedures: 
• The spray dryer was adjusted according to the following parameters:  
Inlet Temperature Compressed air pressure Liquid flow rate 
45ºC 0.2 Mpas. 5ml/min. 
 
• Eudragit E (16 gm) was dissolved in acetone (800 ml) in a conical 
flask (2000 ml capacity) 
• With continuous stirring, PC/SiO2 mixture (16 gm) was gradually 
added to the previous solution. 
• The mixture was spray dried through the spray dryer 
• The dried powder was collected in the cyclone collector  
The collected powder was subjected to two types of stability studies: 
 
3.2.5.1 Stability study for reconstituted powder: 
Two amber glass bottles marked at 100 ml were used for the stability 
study. An equivalent amount of PC/SiO2 coated with eudragit E were added 
to one amber glass bottle and reconstituted with water and the volume was 
completed to the mark (100 ml) and shaken well. The final concentration of 
potassium clavulanate was 50 mg per ml. The other bottle was used to 
reconstitute untreated PC/SiO2 mixture to give a concentration of 50 mg per 
ml. 
The two glass bottles were put at ambient temperature. A sample of 
10 ml was taken from each bottle everyday and subjected to visual and assay 
tests. The stability period was six days. Assay was calculated according to 
the formulae No. 1 
 
52 
3.2.5.2 Stability study (according to WHO stability study guidelines). 
 Powder was packed in small high density polyethylene jars and caps. The 
jars were placed in different incubators at the following conditions:  
1. 30°C and 65 % R.H 
2. 40°C and 75 % R.H. 
3. 45°C and 75 % R.H. 
At the same time an equivalent quantity of active ingredient was packed in 
the same type of jars and subjected to the same accelerated stability study 
conditions. The stability study period was two months. 
A sample of one jar was taken from each incubator every fifteen 
days and tested for appearance, color change and assay. 
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4. RESULTS AND DISCUSSIONS 
 
4.1 Selection of the most compatible solvents 
 
The effect of different solvents on potassium clavulanate was 
summarized in table 4.1. As shown in the table the color of P.C. in water 
was dramatically changed from white to dark red only in 6 days. It was also 
observed that the color of P.C. had changed from orange to red color in the 
same day. This indicates that water is not a suitable solvent to encapsulate 
P.C. However it was mentioned by Jeon et al (2004) that a mixture of drug, 
coating material, sodium lauryl sulfate and Aerosil 200 were uniformly 
dispersed in water and then spray-dried at 70°C with a flow rate of 15 
ml/min. In this case water P.C. is dissolved in water and hence 
encapsulation could not be achieved. 
There was no change in the color in the presence of ether. Acetone, 
chloroform and dichloromethane had less effect on P.C. color while 
methanol, ethanol and isopropyl alcohol had moderate effect. This could be 
attributed to the high volatility of ether followed by acetone. 
The aforementioned results indicated that the most suitable solvents 
are ether, acetone, chloroform and dichloromethane. Accordingly, these 
solvents were used for the selection of the most compatible coating polymer. 
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Table 4.1: Effect of different solvents on Potassium Clavulanate 
 
Days 
Solvent 
mixed with 
P.C. 25/10/2005 temp.14.5ºC 
26/10/2005 
temp.:15ºC
26/10/2005 
temp.:15ºC 
27/10/2005 
Temp.:16ºC 
29/10/2005 
temp.:20ºC 
31/10/2005 
Temp.:15ºC
 Water  White suspension 
Orange 
color Red color 
Dark red 
color 
Red color 
to black 
No further 
change 
 Methanol  White suspension 
Yellowish 
white 
suspension 
No further 
change 
Yellow 
color 
No further 
change 
No further 
change 
 Ethanol  White suspension 
Yellowish 
white 
suspension 
No further 
change 
Yellow 
color 
Yellow to 
orange 
color 
No further 
change 
 Isopropyl  
alcohol 
White 
suspension 
Very slight 
yellowish 
white 
No further 
change 
yellowish 
white 
Yellow 
color 
Orange 
color 
 Acetone  White suspension 
Very slight 
yellowish 
white 
No further 
change 
No further 
change 
yellowish 
white 
No further 
change 
 
dichlorometh
ane 
very slight 
yellowish 
white 
viscous 
suspension 
White 
mixture 
No further 
change 
No further 
change 
Very slight 
change to 
yellowish 
on the 
upper part 
of the tube 
No further 
change 
 Chloroform  
very slight 
yellowish 
white 
viscous 
suspension 
No change No change No change 
Very slight 
change to 
yellowish 
No further 
change 
 Ether  White suspension No change No change No change No change No change 
Drug powder 
(reference.) 
White 
powder No change No change No change 
Very slight 
change to 
yellowish 
No further 
change 
  
 
 
 
 
4.2 Selection of the most suitable coating polymer: 
55 
 
Eudragit E 100 is readily dissolved in all solvents. While ethyl 
cellulose is difficult to dissolve in ether and chloroform; it dissolves better 
in dichloromethane and acetone. Ethyl cellulose is insoluble in water and 
insoluble in acidic or alkaline media, hence it may affect the drug release 
and it is preferred to be excluded. Glycerylmonodtearate has formed a milky 
viscous mixture with ether. It formed transparent agglomerates with 
chloroform and dichloromethane. It dissolves in hot acetone which is 
unacceptable for potassium clavulanate coating. 
Shellac was found difficult to dissolve in all of the solvents. 
Studies using the USP disintegration test for enteric-coated tablets 
have indicated that there is a marked increase in the disintegration time over 
a 6-month storage period for shellac-coated tablets. It is likely that this 
effect is due to the polymerization of shellac, which occurs over storage 
periods of this duration. (Rowe et al, 2006). Therefore shellac was excluded 
and it was concluded that Eudragit E and Ethyl cellulose may be used as 
coating polymers. 
The reasons for selecting Eudragit E as a coating material is due to 
the fact that Eudragit E is insoluble in water but soluble in acid medium 
which may improve the drug release in the acidic medium of the stomach. 
On the other hand, ethyl cellulose is insoluble in either water or acidic fluids 
which may adversely affect the drug release. 
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4.3 Selection of proper ratio between potassium clavulanate and the 
coating material using the spray dryer 
Exp. No. 1: 
The color change of the dried PC/SiO2 and Eudragit E mixture (2: 1) 
is illustrated in figure 4.1. PC/SiO2 and Eudragit E mixture was placed in 
two separate test tubes, 5 ml of water was added to one test tube and the 
other was left as powder. The same was done for the PC/SiO2 for 
comparison. 
 
 
Date 1/4/2007 
 
Date 2/4/2007 
 
Date 3/4/2007 
 
Date 8/4/2007 
 
Figure 4.1 Color change of potassium clavulanate: eudragit E 100(2:1) in acetone 
T = coated PC                                  S = uncoated PC 
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It was observed that the color of both test tube contents had changed to 
brown color after one day. The color on the third day was dark brown in 
both test tubes. After seven days the color of the test tube labeled S 
(untreated PC/SiO2) was black while the coated mixture was dark brown. 
There was no significant color change in the other tests tubes that contain 
the powder. It is thus preferred to do the comparison in the presence of 
water. 
It was concluded that the ratio of the coat to the drug is not appropriate. 
More coating polymer is required or the PC/SiO2 particles would not be 
completely coated  
 
Exp. No. 2: 
The color change of the dried PC/SiO2 and Eudragit E mixture (1: 1) is 
illustrated in figure 4.2 
 
Date 2/4/2007 
 
Date 3/4/2007 
 
Date 8/4/2007 
 
Figure 4.2 color change of potassium clavulanate: eudragit E 100(1:1) in Acetone 
T = coated PC                                  S = uncoated PC 
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It was observed that on the second day the color of the test tube labeled T 
(PC/SiO2 coated with Eudragit E) changed to slight yellowish white color 
while the color of the test tube labeled S that contains PC/SiO2 has changed 
to yellow. After six days the color of the test tube labeled S (untreated 
PC/SiO2) changed to black while the coated mixture was brown. 
It was concluded that the ratio of the coat to the PC/SiO2 (1:1) is much 
better than that of (1:2). More coating may be required or the PC/SiO2 
particles would be incompletely coated.  
 
Exp. No. 3: 
The color change of the dried PC/SiO2 and Eudragit E mixture (1: 2) is 
illustrated in figure 4.3 
 
Date 3/4/2007 
 
Date 8/4/2007 
 
Figure 4.3 Color change of potassium clavulanate: eudragit E 100(1:2) in Acetone 
T = coated PC                                  S = uncoated PC 
After 4 days it was observed that the color of the test tube labeled T 
that contains PC/SiO2 and Eudragit E mixture (1: 2), was yellowish brown 
while the color of the test tube labeled S that contains PC/SiO2, was dark 
brown. 
It was concluded that the ratio of the coat to the PC/SiO2 (2:1) is much 
better than that of (1:2) and more coating may be required or the PC/SiO2 
particles would be incompletely coated. There was no significant difference 
in visual observation between Exp. No. 2 and Exp. No. 3. 
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Exp. No. 4 
The color change of the dried PC/SiO2 and Eudragit E mixture (2: 1) using 
chloroform as a solvent can be seen in figure 4.4 
 
 
Date 14/4/2007 
 
Date 15/4/2007 
 
Date 16/4/2007 
 
Date 17/4/2007 
 
Figure 4.4 Color change of PC/SiO2 : eudragit E 100(2:1) using chloroform 
T = coated PC                                  S = uncoated PC 
 
It was observed that after one day the color in the test tube T 
containing PC/SiO2 : eudragit E 100(1:2), was more intense than that of the 
test tube labeled S which contains untreated PC/SiO2. On the 2nd day the 
color darkened to brown in test tube T and to orange in test tube S. On the 
3rd day the color was dark brown in both test tubes. 
This indicates that there was no coating at all. This is because either 
chloroform has dissolved potassium clavulanate or Eudragit E did not 
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adhere to the PC/SiO2 particles in the presence of chloroform. The coating 
material may have not been sufficient. 
 
Exp. No. 5 
The color change of the dried PC/SiO2 and Eudragit E mixture (2: 1) using 
chloroform as a solvent is illustrated in figure 4.5 
 
 
Date 18/4/2007 
 
Date 19/4/2007 
 
Date 21/4/2007 
 
Figure 4.5 Color change of PC/SiO2 : eudragit E 100(1:1) using chloroform 
T = coated PC                                  S = uncoated PC 
 
 
It was observed that the color change in the tube T (containing 
PC/SiO2 : eudragit E 100(1:2)) is less than that of the tube S but there is a 
significant color change. The conclusion was the same as in Exp. No.4 
 
Exp. No. 6 
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Figure 4.6 shows the color change of the dried PC/SiO2 and Eudragit E 
mixture (1: 2) using chloroform as a solvent. 
Date 26/5/2007 
 
Date 27/5/2007 
 
Date 28/5/2007 
 
Date 29/5/2007 
 
Figure 4.6 Color change of PC/SiO2 : eudragit E 100(1:2) using chloroform 
T = coated PC                                  S = uncoated PC 
It was observed that the color change was the same in both test tubes 
indicating that chloroform was not suitable as a solvent. 
 
 
 
 
 
 
 
 
Exp. No. 7 
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The color change of the dried PC/SiO2 and Eudragit E mixture (1: 1) using 
dichloromethane, as a solvent, was observed. 
 
Date 9/5/2007 Date 10/5/2007 
Date 12/5/2007 
 
 
 
Figure 4.7 Color change of PC/SiO2 : eudragit E 100(1:1) using Dichloromethane 
T = coated PC                                  S = uncoated PC 
In this experiment (Fig. 4.7) the starting ratio was 1:1 since 
dichloromethane is similar to chloroform. It was observed that on the 2nd 
day the color of the test tube labeled T (containing eudragit E and PC/SiO2 
mixture) was more intense than that the test tube S (containing PC/SiO2). 
After three days the color was dark brown in both test tubes. It was indicated 
that dichloromethane might not be a suitable solvent. 
 
 
 
Exp. No. 8 
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The color change of the dried PC/SiO2 and Eudragit E mixture (1: 2), using 
dichloromethane as a solvent, is shown in figure 4.8. 
 
 
Date 26/5/2007 
 
Date 27/5/2007 
 
Date 28/5/2007 
 
Date 29/5/2007 
 
Figure 4.8 Color change of PC/SiO2 : eudragit E 100(1:2) using dichloromethane 
T = coated PC                                  S = uncoated PC 
The color change was the same in both test tubes indicating that 
dichloromethane was not suitable as a solvent and there was no coating at 
all. This is because either dichloromethane has dissolved potassium 
clavulanate or Eudragit E did not adhere. 
 
 
 
 
Exp. No. 9 
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The color change of the dried PC/SiO2 and Eudragit E mixture (2: 1) using 
diethylether as a solvent is illustrated in figure 4.9. 
It was noticed that the prepared mixture was difficult to be forced by 
the spray dryer pump because of the high volatility of ether. Therefore the 
flow rate was increased to 6 ml per minute. 
Date 27/5/2007 Date 28/5/2007 
Date 29/5/2007 Date 30/5/2007 
 
Figure 4.9 Color change of PC/SiO2 : eudragit E 100(2:1) using diethyl ether 
T = coated PC                                  S = uncoated PC 
On the 2nd day there was no significant change in the color of the both test 
tubes. On the 3rd day the color of the test tube S (containing PC/SiO2) was 
more slightly intense than that of the test tube T. After three days the color 
of the test tube T (containing coated PC/SiO2) was slightly yellowish while 
the color of the test tube S was orange. 
These results indicate the likeliness of coating PC/SiO2 using ether as a 
solvent if eudragit E ratio was increased. 
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Exp. No. 10 
In this experiment dried PC/SiO2 and Eudragit E mixture (1: 1) were 
prepared using diethylether as a solvent is illustrated in figure 4.10. 
Similar to the previous experiment (No. 9), it was noticed that the 
prepared mixture was difficult to be forced by the spray dryer pump because 
of the high volatility of ether. Therefore the flow rate was increased to 6ml 
per minute 
 
Date 27/5/2007 Date 28/5/2007 
Date 29/5/2007 Date 1/6/2007 
 
Figure 4.10 Color change of PC/SiO2 : eudragit E 100(1:1) using Diethyl ether 
T = coated PC                                  S = uncoated PC 
It was observed that the change in color was almost the same as in 
experiment No. 9 
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Exp. No. 11 
The color change of the dried PC/SiO2 and Eudragit E mixture (1: 2) using 
diethylether as a solvent, is illustrated in figure 4.11. 
Due to the high volatility of ether and due to the relatively high 
viscosity of the mixture, the nozzle orifice was blocked from time to time. 
 
Date 3/6/2007 
 
Date 5/6/2007 
Date 7/6/2007 Date 10/6/2007 
 
Figure 4.11 Color change of PC/SiO2: eudragit E 100(1:2) using diethyl ether 
T = coated PC                                  S = uncoated PC 
 
It was observed that the color of the test tube T (containing the 
coated PC/SiO2) did not changed during seven days. On the other hand, the 
test tube S color changed from slightly yellowish to orange during the same 
period. 
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It was concluded that diethyl ether was a good solvent in the visual 
test compared to other solvents. 
From the above experiments diethylether was found to be the best 
solvent followed by acetone while chloroform and dichloromethane were 
not suitable solvents  
Ether is very volatile and flammable and mixtures of its vapour with 
oxygen, nitrous oxide, or air at certain concentrations are explosive. It 
should not be used in the presence of an open flame or any electrical 
apparatus liable to produce a spark; precautions should be taken against the 
production of static electrical discharge. Explosive peroxides are generated 
by the atmospheric oxidation of solvent ether and it is dangerous to distil a 
sample which contains peroxides. Its solubility in water is limited (Soluble 1 
in 12 parts of water) (Martindale 2005). However, acetone is considered less 
hazardous (Rowe et al, 2006). It is volatile, clear, colorless liquid; the vapor 
is flammable and miscible with water (Martindale 2005). 
It was concluded from the above that acetone is safer to use than 
ether. Therefore acetone was selected as the solvent and the ratio of the coat 
to PC/SiO2 was 1:1. 
Reasons for selection of acetone as a solvent:  
1. Acetone is readily available. 
2. It is less hazardous than ether 
3. It is less pollutant than diethyl ether since it is water miscible. 
 
 
 
 
4.4 Selection of the most suitable formulae  
Since PC/SiO2 to Eudragit E ratio 1:1 and acetone have been 
selected as the most suitable preparation, the experiment was repeated and 
subjected to the following quality control tests: 
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4.4.1 Visual test to detect any color change: 
The color change of the dried PC/SiO2 and Eudragit E mixture (1:1) is 
illustrated in figure 4.12  
 
Date 06/06/2008 Date 09/06/2008 
 
Date 12/06/2008 
Figure 4.12 color change of potassium clavulanate: eudragit E 100(1:1) in Acetone 
(repeated formulae) 
T = coated PC                                  S = uncoated PC 
As shown above the color of the test tube (S) which contains 
untreated PC/SiO2 has changed to red after three days and changed to dark 
brown color after six days. However the color of the test tube (T) containing 
the coated PC/SiO2 has changed to slightly yellowish white after three days 
and after six days there was no significant color change. 
TT
T
S
S
S
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4.4 2 HPLC determination of clavulanic acid content (yield) 
4.4.2.1 Calibration curve plotting 
Some examples of chromatograms obtained are shown in figures 4.13, 4.14 
and 4.15 
 
 
Fig. 4.13 An HPLC chromatogram for Lithium clavulanate standard solution 
concentration of 0.5 mg/ml. the retention time is 2.122 
 
 
 
Fig. 4.14 An HPLC chromatogram for Lithium clavulanate standard solution 
concentration of 0.125 mg/ml. the retention time is 2.142 
 
 
70 
 
Fig. 4.15 An HPLC chromatogram for Lithium clavulanate standard solution 
concentration of 0.0313 mg/ml. the retention time is 2.132 
 
 
 
 
 
 
 
 
 
 
 
The calibration curve particulars are shown in table 4.2. 
 
Table 4.2.concentrations of the standard solutions and their respective areas 
Concentration (mg/ml) Response (mean Area) SD RSD % 
0.0156 313852 3014 0.96 
0.0313 623712 1106 0.18 
0.0625 1243567 7872 0.63 
0.125 2479030 13195 0.53 
0.25 4933810 13183 0.27 
0.5 9517371 47282 0.5 
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Figure 4.16 Calibration curve of different lithium clavulanate concentrations 
 
The equation of the calibration curve is: 
xy ×=19767408  
Where: 
y  is the response represented by area of the resulted peak 
x  is the concentration of clavulanic acid (mg / ml)  
The slope of the line = 19767408 
 
The linear regression R² = 0.9995 (which indicates that the relationship 
between the instrument response (area) and the concentration is linear). 
 
Calibration factor = 1/19767408 (Figure 4.16). 
 
4.4.2.2 Calculation of yield 
The responses of the chromatographic assay were obtained as peak 
areas. The areas of the standard and sample solutions and their standard 
deviations (SD) and relative standard deviations (RSD) are summarized in 
table 4.3. 
Table 4.3 Peak areas of standard and sample solutions for yield determination. 
Run 
Area of standard 
solution 
(0.125 mg/ml) 
 
SD RSD % Area of sample solution SD RSD%
1 2331391 7035.637 0.3 1507401 29427.91 1.99 
2 2344677   1473778   
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3 2342048   1448755   
Mean 2339372   1476645   
 
 
This experiment is in good agreement with the standard 
specifications since it is mentioned in the USP30-NF25 that the relative 
standard solution RSD of replicate injections should not exceed 2 % 
Clavulanic acid content was calculated according to the formulae: 
 
standard of areapeak 
ion)concentrat standardsample of area(peak contentCA ×=  
 
079.0
2339372
mg/ml)) 0.125 ((1476645contentCA =×= mg/ml 
 
Yield can be calculated as follows: 
Yield (Y1) = (CA content / theoretical CA content in the 
sample)*100 
Yield (Y1) = (0.079 / 0.105)*100 = 75.24% 
A yield of 75% was obtained. 
 
 
4.4 3 Determination of efficiency of coating  
The responses of the chromatographic assay for coating efficiency 
were obtained as peak areas. The areas of the standard and sample solutions 
and their standard deviations (SD) and relative standard deviations (RSD) 
are summarized in table 4.4 
 
Table 4.4: standard and sample area for coating efficiency determination 
Run 
Area of standard 
solution 
(0.125 mg/ml) 
SD RSD % 
Area of sample 
solution 
(0.125 mg/ml) 
SD RSD%
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1 2331391   1324809  
2 2344677   1316863   
3 2342048   1324341   
Mean 2339372 7035.637 0.3 1322004.3 4458.67 0.34 
 
standard of areapeak 
ion)concentrat standardsample of area(peak contentCA ×=  
 
0706.0
2339372
mg/ml)) 0.125 3((1322004.contentCA =×= mg/ml 
 
The yield of uncoated C.A (Y2)  
= (CA content / theoretical CA content in the sample) × 100 
Coating efficiency (C.E.) was calculated as follows: 
The ratio of uncoated CA to the total yield (R1) = (Y2/Y1) ×100 
Where: Y2 is the yield obtained from coating efficiency test. 
Y1 is yield obtained from CA determination test. 
R1 is the ratio of uncoated CA to the total yield 
Coating efficiency (CE) = 100 – R1 
The yield of uncoated C.A (Y2) = (0.0706 / 0.1312) ×100 = 53.8% 
Therefore a yield (Y2) of 53.8% was obtained.  
Y1 is the total yield obtained from CA determination test = 75.24 % 
The ratio of uncoated PC to the total yield (R1) = (Y2/Y1) ×100 
The ratio of uncoated PC = (53.8/75.24) ×100 = 71.5 % 
Coating efficiency = 100-71.5 = 28.5 % 
It means that only 28.5% of PC were completely coated which 
explains the slight color change in the coated mixture. 
 
The reason of the incomplete coating might be due to the following: 
-The amount of Eudragit E was not sufficient. 
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-The coating film around the PC particle may be cracked during the 
spraying 
-Air might be entrapped during spray drying causing the coating film to 
break. 
-A plasticizer may be required to prevent the breakdown of the film 
during handling or during storage. 
-Acetone might produce porous spheres. 
 
Acetone as a solvent was used by Bain et al (1999) in the study of 
the influence of different solvents on spray dried biodegradable 
microsphere. They found that poorer acetonic solvents produced a more 
open porous matrix of increased mean diameter whereas DCM, CFM and 
HAL generated more coherent matrices of greater density and elevated glass 
transition temperature, which significantly retarded drug release. 
Based on the above results acetone has the advantages of producing 
microcapsules with acceptable drug release. 
 
 
 
 
 
 
4.4.4. Determination of drug release (Dissolution test) 
The responses of the chromatographic determination of drug release 
from the different dissolution media were obtained as peak areas. The areas 
of the standard and sample solutions and their standard deviations (SD) and 
relative standard deviations (RSD) are summarized in tables 4.5 to 4.11 
 
Table 4.5 Chromatographic responses of the standard solution of clavulanic 
acid (0.125 mg/ml). 
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Run 
Area of standard solution 
(0.125 mg/ml) 
 
SD RSD % 
1 229352   
2 2256476   
3 2251436   
Mean 2267155 22999 1.01 
 
 
Table 4.6 Chromatographic responses after 10 minutes in 0.1 N HCl 
Drug form Coated PC Untreated PC Reference Brand
Run 1 349708 524831 497006 
Run 2 364923 682808 512233 
Mean area 357316 603820 505620 
SD 10759 111707 10767 
RSD % 3.01 18.5 2.13 
 
 
 
 
 
 
 
Table 4.7 Chromatographic responses after 20 minutes in 0.1 N HCl 
Drug form Coated PC Untreated PC Reference Brand
Run 1 421194 665933 873140 
Run 2 431951 689936 845648 
Mean area 426573 677935 859394 
SD 7606 16973 19440 
RSD % 1.78 2.5 2.26 
 
Table 4.8 Chromatographic responses after 30 minutes in 0.1 N HCl 
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Drug form Coated PC Untreated PC Reference Brand
Run 1 375349 745726 839616 
Run 2 357009 731375 876466 
Mean area 366179 738551 858041 
SD 12968 10148 26057 
RSD % 3.54 1.37 3.04 
 
Table 4.9 Chromatographic responses after 10 minutes in phosphate buffer pH, 
3.5 
Drug form Coated PC Untreated PC Reference Brand
Run 1 979320 1808874 1588460 
Run 2 962134 1788769 1616245 
Mean area 970727 1798822 1602353 
SD 12152 14216 19647 
RSD % 1.25 0.79 1.23 
 
 
 
 
 
 
Table 4.10 Chromatographic responses after 20 minutes in phosphate buffer 
pH, 3.5 
Drug form Coated PC Untreated PC Reference Brand
Run 1 1008186 2038289 2288582 
Run 2 1047016 1994085 2329929 
Mean area 1027601 2016187 2309256 
SD 27457 31257 29237 
RSD % 2.67 1.55 1.27 
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Table 4.11Cchromatographic responses after 30 minutes in phosphate buffer 
pH 3.5 
Drug form Coated PC Untreated PC Reference Brand
Run 1 1194023 1815207 2218590 
Run 2 1221380 1839192 2183920 
Mean area 1207702 1827200 2201255 
SD 19344 16960 24515 
RSD % 1.6 0.93 1.11 
 
 
The amount of the released (dissolved) CA was calculated using the 
formulae: 
 
standard of areapeak 
ion)concentrat standardsample of area(peak contentCA ×=  
 
The ratio of the released (dissolved) CA was calculated using the 
formulae:  
CA ratio = (content of dissolved CA / theoretical CA content) × 100 
 
 
Table 4.12 summarizes the ratio of dissolved PC from different drug 
forms. 
Table 4.12 Ratio of dissolved PC from different drug forms. 
 
Dissolution medium 
0.1N HCL 
Dissolution medium 
phosphate buffer pH 3.5 
Drug form 
10 
minutes 
20 
minutes 
30 
minutes 
10 
minutes 
20 
minutes 
30 
minutes 
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Untreated PC 28.6 % 32.1 % 34.9 % 85.1 % 95.3 % 86.4 % 
Reference Brand 20.0 % 34.1 % 34.1 63.6 % 91.6 % 87.4 % 
Coated PC 16.9 % 20.2 % 17.3 % 45.9 % 48.6 % 57.1 % 
Coated PC 
(considering the yield) 
22.5 % 26.9 % 23.0 % 61.2 % 64.8 % 76.1 % 
 
 
Since the yield of the coated PC was 75 %, the actual dissolved 
ratios are 22.5 %, 26.9 % and 23 % after 10, 20 and 30 minutes respectively 
in 0.1 N HCl dissolution medium. 
The same consideration is applied using phosphate buffer at pH 3.5. 
Hence the actual ratios are 61.2 %, 64.8 % and 76.1 % after 10, 20 and 30 
minutes respectively. 
As specified in USP30-NF25, not less than 80 % CA should be 
dissolved within 30 minutes, both untreated PC and the Reference Brand 
passed the test in case of phosphate buffer pH 3.5. However 76 % of the 
coated PC was dissolved which is close to the lower limit. This may be due 
to the effect of eudragit E. 
In case of dissolution medium of 0.1N HCl, the dissolution of the 
three types of drug form failed and the ratio was below 35 %. The reason 
may be due to the effect of the acid which precipitates potassium 
clavulanate as clavulanic acid which is insoluble in water. 
Jeon et al (2004) that the drug (P.C.) was uniformly added P.C.into 
melted carnauba wax at 80°C to make P.C. surrounded by carnauba wax; 
hence P.C. can be protected from moisture. However, it is important to 
mention that carnauba wax is practically insoluble in water; hence it may 
adversely affect the dissolution of P.C. and its absorption. 
 In addition it has been mentioned by Uddin et al (2002) that the 
ascorbic acid release was found to be slower in the case of carnauba-
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encapsulated ascorbic acid than that made by ethyl cellulose using other 
methods. 
 
4.5 Particle size determination: 
 
It was found that 100 % of the coated powder passed through sieve 
no. 200 ((pore size is 63µ). It means that the particle size range is less than 
63µ. The particle size obtained is within to the microcapsules range (1µ - 
1000µ). 
 
4.6. Stability study for reconstituted powder at ambient temperature: 
The stability study of the reconstituted powder of the coated PC as 
well as the untreated PC powder is illustrated in table 4.13 - 4.17. The study 
was carried out for six days. 
Table 4.13 Chromatographic responses on the 1st day (initial) 
Drug form Standard solution 
(0.125 mg/ml) 
Coated PC 
(0.100 mg/ml) 
Untreated PC 
(0.125 mg/ml) 
Run 1 2255726 1452063 1808874 
Run 2 2285179 1463466  
Run 3 2239814 1456389 1788769 
Mean area 2260240 1457273 1798822 
SD 23017 5765 14216 
RSD % 1.02 0.4 0.79 
Assay  - 80.6 % 85.8 % 
Table 4.14 Chromatographic responses after one day 
Drug form Standard solution 
(0.125 mg/ml) 
Coated PC 
(0.100 mg/ml) 
Untreated PC 
(0.125 mg/ml) 
Run 1 2237708 1436353 1801067 
Run 2 2217163 1461801 1797111 
Mean area 2227436 1449077 1799089 
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SD 14528 17994 2797 
RSD % 0.65 1.24 0.16 
Assay  - 81.3 % 80.8 % 
 
Table 4.15 Chromatographic responses after two days 
Drug form Standard solution 
(0.125 mg/ml) 
Coated PC 
(0.100 mg/ml) 
Untreated PC 
(0.125 mg/ml) 
Run 1 2344699 1401803 1800755 
Run 2 2292836 1415805 1746591 
Run 3 2333165 1418765 1796734 
Mean area 2323567 1412124 1781360 
SD 27231 9060 30178 
RSD % 1.17 0.64 1.69 
Assay  - 75.9 % 76.7 % 
 
Table 4.16 Chromatographic responses after three days 
Drug form Standard solution 
(0.125 mg/ml) 
Coated PC 
(0.100 mg/ml) 
Untreated PC 
(0.125 mg/ml) 
Run 1 2419123 1320653 1769432 
Run 2 2425620 1337515 1744776 
Run 3 2499910 1331546 1776335 
Mean area 2448218 1329905 1763514 
SD 44885 8550 16591 
RSD % 1.83 0.64 0.94 
Assay  - 67.9 % 72.0 % 
 
Table 4.17 Chromatographic responses after six days 
Drug form Standard solution 
(0.125 mg/ml) 
Coated PC 
(0.100 mg/ml) 
Untreated PC 
(0.125 mg/ml) 
Run 1 2327911 76192 1278630 
Run 2 2334347 755682 1284699 
Mean area 2331129 758797 1281665 
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SD 4551 
 
4405 4291 
RSD % 0.2 0.58 0.33 
Assay  - 41.0 % 55.4 % 
 
Table 4.18 summarizes the stability study results of the reconstituted 
powder. 
 
Table 4.18 Stability study results of the reconstituted powder  
 Assay at intervals(days) 
Drug form Initial assay One day Two days Three days Six days 
Coated PC 80.6 % 81.3 % 75.9 % 67.9 % 41.0 % 
Untreated PC 85.8 % 80.8 % 76.7 % 72.0 % 55.4 % 
 
From the above table (4.18) it was observed that the degradation of 
PC in the coated PC in the first two days was low compared with that of 
untreated PC. However the degradation was higher in the rest of the days. 
 
 
 
 
 
 
 
4.7. Stability study at 30, 40 and 45ºC. 
The stability study of the powder of the coated PC as well as the untreated 
PC powder is illustrated in table 4.19, 4.20 and 4.21. The study was carried 
out for two months. 
 
Table 4.19 Summary of stability study of coated PC at 30°C and 65% R.H. 
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Intervals (days) 
 Coated PC Untreated PC 
Test  Zero 
time 
15 
days 
30 days 45 
days 
60 
days 
Zero 
time 
15 
days 
30 
days 
45 
days 
60 
days 
Description  Very 
Small 
granules  
No 
change 
No 
change  
No 
change 
No 
change
Fine 
powder  
No 
change  
No 
change
No 
change
No 
change
Color  White  Off 
white 
Slight 
yellowish 
white 
No 
change 
No 
change
White  yellow Dark 
yellow 
Slight 
brown 
Slight 
brown
Assay as 
CA % 
79.5 74.5 37.5 34.2 34.8 83.3 79.4 49.3 51.3 46.5 
 
 
From the above table it was observed that the degradation of P.C. in 
the coated form was higher than that of the untreated form. Silicone dioxide 
in the untreated P.C. might play a role in the protection of P.C. at 30°C and 
65% R.H. 
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Table 4.20 Summary of d stability study of coated PC at 40°C and 75% 
R.H. 
Intervals (days) 
 Coated PC Untreated PC 
Test  Zero 
time 
15 
days 
30 
days 
45 days 60 days Zero 
time 
15 
days 
30 days 45 
days 
60 
days 
Description  Very 
Small 
granules  
No 
change  
No 
change  
Aggregated 
granules 
Aggreg. 
granules
Fine 
powder 
No 
change 
Aggreg. 
powder 
Caked 
powder
Caked 
powder
Color  White  Yellow  Light 
brown 
Brown  brown White  yellow Brown  brown brown 
Assay as 
CA % 
79.5 43.2 35.5 38.7 10.16 83.3 20.7 15.7 12.3 2.6 
 
 
The degradation of P.C. in the coated form was lower than that of the 
untreated one (table 4.20). It means that the coat might increase the stability 
of P.C. 
 
 
Table 4.21 Summary of stability study of coated PC at 45°C and 75% R.H. 
Intervals (days) 
 Coated PC Untreated PC 
Test  Zero 
time 
15 days 30 
days 
45 
days 
60 
days 
Zero 
time 
15 
days 
30 
days 
45 
days 
60 
days 
Description  Very 
Small 
granules  
Aggregated 
granules 
No  
Further 
change 
No  
Further 
change 
No  
Further 
change 
Fine 
powder 
Caked 
powder
Caked 
powder 
Caked 
powder
Caked 
powder
Color  White  yellow brown brown Dark 
brown 
White  yellow brown brown Dark 
brown 
Assay as 
CA % 
79.5 24.9 15.3 12.3 5.1 83.3 19.8 15.3 12.4 2.4 
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Table 4.21 shows that the degradation of P.C. was almost same in 
both drug forms indicating that the coating material is not effective at a 
temperature of 45°C or above. 
In general it can be concluded from table 4.19, 4.20 and 4.21 that 
the degradation of P.C. is strongly correlated to the change of its color. It 
can also be concluded that P.C. is highly sensitive to temperature as it has a 
major effect on P.C. degradation. 
The CA stability was investigated at different values of pH (4.0–8.0) 
and temperature (20–45°C) by V.C. Santos et al, (2009) and the best 
conditions were met at a pH 6.0–7.2 and 20°C. 
 
It was mentioned by Jeon et al (2004) that drug (P.C.) was 
uniformly added into melted carnauba wax at 80°C and then cooled at a 
refrigerator. P.C. under this condition may undergo degradation. Therefore 
P.C. might be protected against moisture by coating or addition of a 
moisture barrier but cannot be protected from high temperature by such 
methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
5- CONCLUSION 
Since all β -lactam compounds are readily hydrolyzed in water 
(moisture), they are formulated as solid dosage forms. Once the powder for 
suspension is reconstituted, it should be used at the time of reconstitution for 
parenteral preparations or within one or two weeks from the time of 
reconstitution for oral preparations. Preparations of antibiotics that contain 
clavulanic acid should be prepared and manufactured under specific 
conditions (below 25ºC and not more than 27 % R.H.). Additionally these 
preparations once opened or reconstituted with water, should be used within 
a specific period of time (one week for syrup) and stored in a refrigerator to 
prevent or slow the degradation of clavulanic acid. 
In the present study a highly moisture and temperature sensitive 
compound, potassium clavulanate, was microencapsulated by using spray 
drying technique in order to improve its stability.  
Different coating polymers and organic solvents were screened and 
investigated to select the most appropriate polymer and solvent. Acetone 
and Eudragit E have been selected. 
The resultant microcapsules were subjected to different tests. A 
particle size range of less than 63µ has been achieved. A yield of about 75% 
was obtained and around 30% of the particles were completely coated. The 
percentage dissolved in 30 minutes was 76%. The stability study results 
showed that the microcapsules are more stable at 40ºC and 75% R.H. than 
the untreated potassium clavulanate. 
This study assessed the feasibility of microencapsulating potassium 
clavulanate and other moisture sensitive compounds by spray drying 
technique. 
The control of spray drying conditions as well as proper selection of 
the coating material and the solvent play a major role in the final product 
specifications including drug release. 
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The final yield can be improved by adjusting the spray dryer 
parameters such as liquid flow rate and compressed air pressure as well as 
selection of a proper nebulizer. 
It is recommended that addition of a suitable plasticizer may 
improve the coating efficiency by preventing the breakdown of the film coat 
during production and/or storage. Proper manipulation of the plasticizer to 
coat ratio may result in a stable compound with good dissolution profile. 
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7-APPENDICES 
 
7.1 Appendex A. 
 
Chromatograms of defferent lithium clavulanate standard 
concentrations prepared for calibration curve: 
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7.2 Appendix B. 
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Chromatographic responses of standard and sample solutions for the 
determination of yield. 
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7.3 Appendix C. 
 
 
Chromatographic responses of standard and sample solutions for the 
determination of coating effeciency 
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7.4 Appendix D. 
 
Stability study  
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